<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23331510</article-id><article-id pub-id-type="pmc">3556334</article-id><article-id pub-id-type="publisher-id">1471-2334-13-22</article-id><article-id pub-id-type="doi">10.1186/1471-2334-13-22</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Salahuddin</surname><given-names>Nawal</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>salahuddin.nawal@gmail.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Ali</surname><given-names>Farheen</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>farheen.ali@aku.edu</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Hasan</surname><given-names>Zahra</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>zahra.hasan@aku.edu</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Rao</surname><given-names>Nisar</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>nisar.rao@aku.edu</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Aqeel</surname><given-names>Masooma</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>aqeel.masooma@gmail.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Mahmood</surname><given-names>Faisal</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>faisal.mahmood@aku.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Consultant Department of Adult Critical Care Medicine, King Faisal Specialist Hospital &amp; Research Centre, Riyadh, Saudi Arabia</aff><aff id="I2"><label>2</label>Section of Infectious Disease, Department of Medicine, Aga Khan University, Karachi, Pakistan</aff><aff id="I3"><label>3</label>Department of Pathology and Microbiology, Aga Khan University, Karachi, Pakistan</aff><aff id="I4"><label>4</label>Department of Pulmonology, Ojha Institute of Chest Diseases, Karachi, Pakistan</aff><aff id="I5"><label>5</label>Section of Pulmonary and Critical Care Medicine, Department of Medicine, Aga Khan University, Karachi, Pakistan</aff><aff id="I6"><label>6</label>Section of Infectious Disease, Department of Medicine, Aga Khan University, Karachi, Pakistan</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>1</month><year>2013</year></pub-date><volume>13</volume><fpage>22</fpage><lpage>22</lpage><history><date date-type="received"><day>29</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>11</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>Copyright ©2013 Salahuddin et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Salahuddin et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2334/13/22"></self-uri><abstract><sec><title><offsets xml_i="4448" xml_f="4458" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4469" xml_f="4524" txt_i="22" txt_f="77">Vitamin D enhances host protective immune responses to </offsets><italic><offsets xml_i="4532" xml_f="4558" txt_i="77" txt_f="103">Mycobacterium tuberculosis</offsets></italic><offsets xml_i="4567" xml_f="4807" txt_i="103" txt_f="343"> by suppressing Interferon-gamma (IFN-g) and reducing disease associated inflammation in the host. The objectives of this study were to determine whether vitamin D supplementation to patients with tuberculosis (TB) could influence recovery.</offsets></p></sec><sec><title><offsets xml_i="4829" xml_f="4836" txt_i="345" txt_f="352">Methods</offsets></title><p><offsets xml_i="4847" xml_f="4972" txt_i="353" txt_f="478">Two hundred and fifty nine patients with pulmonary TB were randomized to receive either 600,000 IU of Intramuscular vitamin D</offsets><sub><offsets xml_i="4977" xml_f="4978" txt_i="478" txt_f="479">3</offsets></sub><offsets xml_i="4984" xml_f="5112" txt_i="479" txt_f="607"> or placebo for 2 doses. Assessments were performed at 4, 8 and 12 weeks. Early secreted and T cell activated 6 kDa (ESAT6) and </offsets><italic><offsets xml_i="5120" xml_f="5146" txt_i="607" txt_f="633">Mycobacterium tuberculosis</offsets></italic><offsets xml_i="5155" xml_f="5359" txt_i="633" txt_f="837"> sonicate (MTBs) antigen induced whole blood stimulated IFN-g responses were measured at 0 and 12 weeks. Statistical comparisons between outcome variables at 0 and 12 weeks were performed using Student’s </offsets><italic><offsets xml_i="5367" xml_f="5368" txt_i="837" txt_f="838">t</offsets></italic><offsets xml_i="5377" xml_f="5390" txt_i="838" txt_f="851">-test and Chi</offsets><sup><offsets xml_i="5395" xml_f="5396" txt_i="851" txt_f="852">2</offsets></sup><offsets xml_i="5402" xml_f="5409" txt_i="852" txt_f="859"> tests.</offsets></p></sec><sec><title><offsets xml_i="5431" xml_f="5438" txt_i="861" txt_f="868">Results</offsets></title><p><offsets xml_i="5449" xml_f="5523" txt_i="869" txt_f="943">After 12 weeks, the vitamin D supplemented arm demonstrated significantly </offsets><italic><offsets xml_i="5531" xml_f="5538" txt_i="943" txt_f="950">greater</offsets></italic><offsets xml_i="5547" xml_f="5627" txt_i="950" txt_f="1030"> mean weight gain (kg) + 3.75, (3.16 – 4.34) versus + 2.61 (95% CI 1.99 – 3.23) </offsets><italic><offsets xml_i="5635" xml_f="5636" txt_i="1030" txt_f="1031">p</offsets></italic><offsets xml_i="5645" xml_f="5656" txt_i="1031" txt_f="1042"> 0.009 and </offsets><italic><offsets xml_i="5664" xml_f="5670" txt_i="1042" txt_f="1048">lesser</offsets></italic><offsets xml_i="5679" xml_f="5757" txt_i="1048" txt_f="1126"> residual disease by chest radiograph; number of zones involved 1.35 v/s 1.82 </offsets><italic><offsets xml_i="5765" xml_f="5766" txt_i="1126" txt_f="1127">p</offsets></italic><offsets xml_i="5775" xml_f="5875" txt_i="1127" txt_f="1227"> 0.004 (95% CI 0.15, 0.79) and 50% or greater reduction in cavity size 106 (89.8%) v/s 111 (94.8%), </offsets><italic><offsets xml_i="5883" xml_f="5884" txt_i="1227" txt_f="1228">p</offsets></italic><offsets xml_i="5893" xml_f="6059" txt_i="1228" txt_f="1394"> 0.035. Vitamin D supplementation led to significant increase in MTBs-induced IFN-g secretion in patients with baseline ‘Deficient’ 25-hydroxyvitamin D serum levels (</offsets><italic><offsets xml_i="6067" xml_f="6068" txt_i="1394" txt_f="1395">p</offsets></italic><offsets xml_i="6077" xml_f="6085" txt_i="1395" txt_f="1403"> 0.021).</offsets></p></sec><sec><title><offsets xml_i="6107" xml_f="6118" txt_i="1405" txt_f="1416">Conclusions</offsets></title><p><offsets xml_i="6129" xml_f="6417" txt_i="1417" txt_f="1705">Supplementation with high doses of vitamin D accelerated clinical, radiographic improvement in all TB patients and increased host immune activation in patients with baseline ‘Deficient’ serum vitamin D levels. These results suggest a therapeutic role for vitamin D in the treatment of TB.</offsets></p></sec><sec><title><offsets xml_i="6439" xml_f="6457" txt_i="1707" txt_f="1725">Trial registration</offsets></title><p><offsets xml_i="6468" xml_f="6492" txt_i="1726" txt_f="1750">ClinicalTrials.gov; No. </offsets><italic><offsets xml_i="6500" xml_f="6511" txt_i="1750" txt_f="1761">NCT01130311</offsets></italic><offsets xml_i="6520" xml_f="6527" txt_i="1761" txt_f="1768">; URL: </offsets><italic><offsets xml_i="6535" xml_f="6553" txt_i="1768" txt_f="1786">clinicaltrials.gov</offsets></italic></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="6624" xml_f="6634" txt_i="1795" txt_f="1805">Background</offsets></title><p><offsets xml_i="6645" xml_f="6687" txt_i="1806" txt_f="1848">Vitamin D is now known to be essential to </offsets><italic><offsets xml_i="6695" xml_f="6721" txt_i="1848" txt_f="1874">Mycobacterium tuberculosis</offsets></italic><offsets xml_i="6730" xml_f="6990" txt_i="1874" txt_f="2134"> (MTB) containment and killing through activation of 25-hydroxyvitamin D receptors (VDRs) present on all immune cells. Stimulation of Toll-like receptors (TLRs) on monocytes and macrophages by MTB antigens leads to an up-regulation of VDRs. Binding of 1,25(OH)</offsets><sub><offsets xml_i="6995" xml_f="6996" txt_i="2134" txt_f="2135">2</offsets></sub><offsets xml_i="7002" xml_f="7004" txt_i="2135" txt_f="2137"> D</offsets><sub><offsets xml_i="7009" xml_f="7010" txt_i="2137" txt_f="2138">3</offsets></sub><offsets xml_i="7016" xml_f="7091" txt_i="2138" txt_f="2213"> activates VDRs and induces cathelicidin-mediated killing of Mycobacteria
[</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7122" xml_f="7123" txt_i="2213" txt_f="2214">1</offsets></xref><offsets xml_i="7130" xml_f="7131" txt_i="2214" txt_f="2215">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7162" xml_f="7163" txt_i="2215" txt_f="2216">2</offsets></xref><offsets xml_i="7170" xml_f="7336" txt_i="2216" txt_f="2382">]. Susceptibility to tuberculosis (TB) and risk of progression from infection to disease, tends to occur more often in patients with low 25- hydroxyvitamin D levels
[</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7367" xml_f="7368" txt_i="2382" txt_f="2383">3</offsets></xref><offsets xml_i="7375" xml_f="7376" txt_i="2383" txt_f="2384">-</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7407" xml_f="7408" txt_i="2384" txt_f="2385">5</offsets></xref><offsets xml_i="7415" xml_f="7570" txt_i="2385" txt_f="2540">] while, close contacts of TB patients display a 5-fold increased risk of contracting TB with each relative 1–log decrement in 25- hydroxyvitamin D level
[</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7601" xml_f="7602" txt_i="2540" txt_f="2541">6</offsets></xref><offsets xml_i="7609" xml_f="7843" txt_i="2541" txt_f="2775">]. Historically cod liver oil and sunshine, both excellent sources of 25-hydroxyvitamin D, were used for the treatment of TB. More recently, single doses of 25-hydroxyvitamin D have been demonstrated to enhance mycobacterial killing
[</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7874" xml_f="7875" txt_i="2775" txt_f="2776">7</offsets></xref><offsets xml_i="7882" xml_f="7972" txt_i="2776" txt_f="2866">]. However two recent Vitamin D supplementation trials failed to demonstrate any benefit
[</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8003" xml_f="8004" txt_i="2866" txt_f="2867">8</offsets></xref><offsets xml_i="8011" xml_f="8012" txt_i="2867" txt_f="2868">,</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8043" xml_f="8044" txt_i="2868" txt_f="2869">9</offsets></xref><offsets xml_i="8051" xml_f="8131" txt_i="2869" txt_f="2949">] possibly due to the low doses used. We hypothesized that supplementation with </offsets><italic><offsets xml_i="8139" xml_f="8156" txt_i="2949" txt_f="2966">therapeutic doses</offsets></italic><offsets xml_i="8165" xml_f="8353" txt_i="2966" txt_f="3154"> of vitamin D in patients with active TB, may improve outcomes. Our study objectives were to determine the effects of vitamin D supplementation on clinical indicators and immune responses.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="8394" xml_f="8401" txt_i="3156" txt_f="3163">Methods</offsets></title><sec><title><offsets xml_i="8421" xml_f="8433" txt_i="3164" txt_f="3176">Study design</offsets></title><p><offsets xml_i="8444" xml_f="9838" txt_i="3177" txt_f="4571">This was a randomized double blinded, multi-centre, placebo-controlled clinical trial. The study was approved by the institutional review boards of the participating centres; Aga Khan University Hospital (ERC approval no. 1238-Med/ERC-09) and Ojha Institute of Chest Diseases, Dow University Hospital (IRB-94/DUHS-09) and is listed on clinicaltrials.gov (NCT01130311). The trial was funded through a grant obtained from the Aga Khan University Research Council (URC grant No. 0000058579). The study was conducted from October 2009 to July 2010 with enrolment of the first participant in October 2009 and last participant in April 2010. The protocol was made available at clinicaltrials.gov in May 2010. All patients provided written, informed consent prior to participation. Consecutive adult patients (≥16 years) with smear positive, active pulmonary TB diagnosed within one week and enrolled at outpatient TB clinics were included. Based on clinical history taking and clinical records, patients with extra- pulmonary TB, human immunodeficiency virus (HIV) infection, hepatic disease, renal failure, malignancy, diabetes mellitus, pregnancy, sarcoidosis, hyperparathyroidism or those taking any corticosteroids, immunosuppressive agents, thiazide diuretics or drugs known to interfere with vitamin D levels (phenytoin, phenobarbital, carbamazepine, theophylline) were excluded from the study.</offsets></p></sec><sec><title><offsets xml_i="9860" xml_f="9899" txt_i="4573" txt_f="4612">Primary and secondary outcome variables</offsets></title><p><offsets xml_i="9910" xml_f="10350" txt_i="4613" txt_f="5053">The primary outcome variables were differences in weight gained and resolution of chest radiograph abnormalities. Secondary outcomes were differences in whole blood cell antigen-stimulated Interferon-gamma(IFN-g) responses, differences in sputum conversion rates and improvements in the TB score. An ad hoc analysis looked at the differences in the cytokine response, and clinical recovery based on differences in baseline vitamin D status.</offsets></p></sec><sec><title><offsets xml_i="10372" xml_f="10384" txt_i="5055" txt_f="5067">Measurements</offsets></title><p><offsets xml_i="10395" xml_f="11215" txt_i="5068" txt_f="5888">Baseline clinical data, chest radiographs, sputum and blood samples for 25 hydroxyvitamin D assay and cytokine analysis were collected. The randomization sequence was generated by the Dept. of Pharmacy, Aga Khan University, who were responsible for dispensing the study drug/placebo. The study co-ordinator and physician available at the study site enrolled participants who were eligible. All patients continued to receive Directly Observed Therapy (DOTS) with 2 months of 4 antituberculous drugs [Isoniazid, Rifampicin, Ethambutol and Pyrazinamide] followed by 6 months of Isoniazid and Ethambutol. Eligible patients were screened, enrolled and randomized by a computer-generated stratified, random assignments list (block randomization). The 2 study arms were either administered 600,000 IU of intramuscular vitamin D</offsets><sub><offsets xml_i="11220" xml_f="11221" txt_i="5888" txt_f="5889">3</offsets></sub><offsets xml_i="11227" xml_f="11521" txt_i="5889" txt_f="6183"> (cholecalciferol) for 2 doses one month apart or an equivalent volume of normal saline matched for colour. Doses were given at enrolment and repeated 4 weeks from baseline. This dosage formulation of vitamin D is as recommended for vitamin D supplementation by the Pakistan Endocrine Society [</offsets><italic><offsets xml_i="11529" xml_f="11551" txt_i="6183" txt_f="6205">personal communication</offsets></italic><offsets xml_i="11560" xml_f="11697" txt_i="6205" txt_f="6342">]. The patient, primary physicians, investigator physicians, study coordinator, site assistants were blinded to the treatment allocation.</offsets></p><p><offsets xml_i="11704" xml_f="11969" txt_i="6343" txt_f="6608">Clinical assessments and sputum microscopic examinations were performed at all visits (0, 4, 8 and 12 weeks of therapy). Chest radiographs and blood samples for cytokine assays were obtained at 0 and 12 weeks. Clinical examination was used to calculate a TB score
[</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="12001" xml_f="12003" txt_i="6608" txt_f="6610">10</offsets></xref><offsets xml_i="12010" xml_f="12764" txt_i="6610" txt_f="7364">] for all visits. The TB score is a validated assessment tool developed to objectively measure change in the clinical status of TB patients. Its components include self-reported symptoms (cough, shortness of breath, night sweats, chest pain, haemoptysis), clinical signs (tachycardia, pallor, fever, auscultatory findings) body mass index (BMI) and mid-upper arm circumference (MUAC). Mid Upper Arm Circumference (MUAC) was recorded to an accuracy of 0.5 cm at the mid-point of the acromion and the olecranon process over the biceps muscle of the non-dominant arm, using a non-stretchable measuring tape. Height was recorded in metres, and weight in kilograms using a standard weighing machine at all visits. Body Mass Index (BMI) = weight (kg)/height (m</offsets><sup><offsets xml_i="12769" xml_f="12770" txt_i="7364" txt_f="7365">2</offsets></sup><offsets xml_i="12776" xml_f="13119" txt_i="7365" txt_f="7702">). The TB score achieved can range from 0–13. TB scores were further divided into 3 severity classes; Severity Class I (TB score 0 to 5), Class II (TB score 6 – 7) and Class III (TB score ≥ 8). Baseline 25 hydroxyvitamin D levels were measured and divided into ‘Optimal’ &gt; 30 ng/ml, ‘Insufficient’ 20–30 ng/ml and ‘Deficient’ &lt; 20 ng/ml.</offsets></p><p><offsets xml_i="13126" xml_f="13436" txt_i="7703" txt_f="8013">Chest X-rays were interpreted independently by 2 consultant pulmonologists who were blinded to the treatment allocation process. Three separate methods of disease categorization were employed. This included classification into ‘minimally’, ‘moderately’ and far advanced categories of radiographic infiltrates
[</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="13468" xml_f="13470" txt_i="8013" txt_f="8015">11</offsets></xref><offsets xml_i="13477" xml_f="13478" txt_i="8015" txt_f="8016">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="13510" xml_f="13512" txt_i="8016" txt_f="8018">12</offsets></xref><offsets xml_i="13519" xml_f="13730" txt_i="8018" txt_f="8229">]. Secondly, cavity size and change in size from 0 to 12 weeks was recorded. Thirdly, the bilateral lung fields were divided in to 3 zones (6 total) and disease extent was recorded as ‘Zone involvement’ (Table 
</offsets><xref ref-type="table" rid="T1"><offsets xml_i="13762" xml_f="13763" txt_i="8229" txt_f="8230">1</offsets></xref><offsets xml_i="13770" xml_f="13772" txt_i="8230" txt_f="8232">).</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="13820" xml_f="13827" txt_i="8233" txt_f="8240">Table 1</offsets></label><caption><p><offsets xml_i="13847" xml_f="13921" txt_i="8240" txt_f="8314">Baseline characteristics in the vitamin D and placebo study arms (N = 259)</offsets></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold><offsets xml_i="14143" xml_f="14166" txt_i="8315" txt_f="8338">Baseline characteristic</offsets></bold><hr></hr></th><th colspan="2" align="center" valign="bottom"><bold><offsets xml_i="14240" xml_f="14253" txt_i="8338" txt_f="8351">Randomization</offsets></bold><hr></hr></th></tr><tr><th align="left"><offsets xml_i="14300" xml_f="14301" txt_i="8351" txt_f="8352"> </offsets></th><th align="center"><bold><offsets xml_i="14331" xml_f="14358" txt_i="8352" txt_f="8379">Drug intervention (n = 132)</offsets></bold></th><th align="center"><bold><offsets xml_i="14395" xml_f="14425" txt_i="8379" txt_f="8409">Placebo intervention (n = 127)</offsets></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><offsets xml_i="14507" xml_f="14529" txt_i="8409" txt_f="8431">Age (years), Mean ± SD</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="14578" xml_f="14589" txt_i="8432" txt_f="8443">27.8 ± 13.2</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="14638" xml_f="14649" txt_i="8444" txt_f="8455">28.3 ± 14.1</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="14705" xml_f="14716" txt_i="8456" txt_f="8467">Gender, Men</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="14765" xml_f="14774" txt_i="8468" txt_f="8477">71 (53.8)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="14823" xml_f="14832" txt_i="8478" txt_f="8487">70 (55.1)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="14888" xml_f="14910" txt_i="8488" txt_f="8510">Weight (kg), Mean ± SD</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="14959" xml_f="14969" txt_i="8511" txt_f="8521">45.2 ± 7.6</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15018" xml_f="15028" txt_i="8522" txt_f="8532">45.6 ± 9.0</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="15084" xml_f="15101" txt_i="8533" txt_f="8550">BMI, Mean (range)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15150" xml_f="15162" txt_i="8551" txt_f="8563">17.2 (11–25)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15211" xml_f="15223" txt_i="8564" txt_f="8576">17.3 (11–27)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="15279" xml_f="15297" txt_i="8577" txt_f="8595">MUAC (cm), (range)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15346" xml_f="15358" txt_i="8596" txt_f="8608">21.2 (14–30)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15407" xml_f="15419" txt_i="8609" txt_f="8621">21.1 (15–32)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="15475" xml_f="15500" txt_i="8622" txt_f="8647">Disease Symptom(s)present</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15549" xml_f="15550" txt_i="8648" txt_f="8649"> </offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15599" xml_f="15600" txt_i="8650" txt_f="8651"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="15656" xml_f="15662" txt_i="8652" txt_f="8658"> Cough</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15711" xml_f="15721" txt_i="8659" txt_f="8669">127 (96.2)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15770" xml_f="15780" txt_i="8670" txt_f="8680">125 (98.4)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="15836" xml_f="15848" txt_i="8681" txt_f="8693"> Haemoptysis</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15897" xml_f="15906" txt_i="8694" txt_f="8703">30 (22.7)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="15955" xml_f="15964" txt_i="8704" txt_f="8713">34 (26.8)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="16020" xml_f="16029" txt_i="8714" txt_f="8723"> Dyspnoea</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16078" xml_f="16087" txt_i="8724" txt_f="8733">84 (63.6)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16136" xml_f="16145" txt_i="8734" txt_f="8743">85 (66.9)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="16201" xml_f="16212" txt_i="8744" txt_f="8755"> Chest pain</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16261" xml_f="16270" txt_i="8756" txt_f="8765">84 (63.6)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16319" xml_f="16328" txt_i="8766" txt_f="8775">84 (66.1)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="16384" xml_f="16397" txt_i="8776" txt_f="8789"> Night sweats</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16446" xml_f="16455" txt_i="8790" txt_f="8799">69 (52.3)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16504" xml_f="16513" txt_i="8800" txt_f="8809">55 (43.3)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="16569" xml_f="16586" txt_i="8810" txt_f="8827"> Pale conjunctiva</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16635" xml_f="16642" txt_i="8828" txt_f="8835">70 (53)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16691" xml_f="16700" txt_i="8836" txt_f="8845">67 (52.8)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="16756" xml_f="16768" txt_i="8846" txt_f="8858"> Tachycardia</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16817" xml_f="16826" txt_i="8859" txt_f="8868">87 (65.9)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16875" xml_f="16884" txt_i="8869" txt_f="8878">86 (67.7)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="16940" xml_f="16946" txt_i="8879" txt_f="8885"> Fever</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="16995" xml_f="17004" txt_i="8886" txt_f="8895">49 (37.1)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17053" xml_f="17062" txt_i="8896" txt_f="8905">68 (53.5)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17118" xml_f="17131" txt_i="8906" txt_f="8919"> Crepitations</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17180" xml_f="17189" txt_i="8920" txt_f="8929">50 (37.9)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17238" xml_f="17247" txt_i="8930" txt_f="8939">38 (29.9)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17303" xml_f="17311" txt_i="8940" txt_f="8948"> Rhonchi</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17360" xml_f="17369" txt_i="8949" txt_f="8958">19 (14.4)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17418" xml_f="17427" txt_i="8959" txt_f="8968">21 (16.5)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17483" xml_f="17505" txt_i="8969" txt_f="8991"> Reduced breath sounds</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17554" xml_f="17563" txt_i="8992" txt_f="9001">26 (19.7)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17612" xml_f="17621" txt_i="9002" txt_f="9011">20 (15.7)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17677" xml_f="17703" txt_i="9012" txt_f="9038">TB score, Mean ± SD, 95 CI</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17752" xml_f="17773" txt_i="9039" txt_f="9060">6.68 ± 2.04, 6.3-7.03</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17822" xml_f="17843" txt_i="9061" txt_f="9082">6.85 ± 2.50, 6.4-7.29</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="17899" xml_f="17939" txt_i="9083" txt_f="9123">Distribution by Severity Class/TB score*</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="17988" xml_f="17989" txt_i="9124" txt_f="9125"> </offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18038" xml_f="18039" txt_i="9126" txt_f="9127"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18095" xml_f="18109" txt_i="9128" txt_f="9142"> Class I/0 – 5</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18158" xml_f="18167" txt_i="9143" txt_f="9152">32 (24.2)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18216" xml_f="18225" txt_i="9153" txt_f="9162">40 (31.5)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18281" xml_f="18296" txt_i="9163" txt_f="9178"> Class II/6 – 7</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18345" xml_f="18354" txt_i="9179" txt_f="9188">51 (38.6)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18403" xml_f="18412" txt_i="9189" txt_f="9198">41 (32.3)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18468" xml_f="18482" txt_i="9199" txt_f="9213"> Class III/≥ 8</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18531" xml_f="18540" txt_i="9214" txt_f="9223">49 (37.1)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18589" xml_f="18598" txt_i="9224" txt_f="9233">46 (36.2)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18654" xml_f="18668" txt_i="9234" txt_f="9248">Serum-25-(OH)D</offsets><sub><offsets xml_i="18673" xml_f="18674" txt_i="9248" txt_f="9249">3</offsets></sub><offsets xml_i="18680" xml_f="18699" txt_i="9249" txt_f="9268"> levels; Mean, (SD)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18748" xml_f="18760" txt_i="9269" txt_f="9281">20.58 ± 8.51</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18809" xml_f="18822" txt_i="9282" txt_f="9295">22.87 ± 10.33</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="18878" xml_f="18885" txt_i="9296" txt_f="9303">25(OH)D</offsets><sub><offsets xml_i="18890" xml_f="18891" txt_i="9303" txt_f="9304">3</offsets></sub><offsets xml_i="18897" xml_f="18920" txt_i="9304" txt_f="9324"> &gt;30 ng/ml (Optimal)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="18969" xml_f="18978" txt_i="9325" txt_f="9334">18 (13.6)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19027" xml_f="19036" txt_i="9335" txt_f="9344">25 (19.7)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19092" xml_f="19099" txt_i="9345" txt_f="9352">25(OH)D</offsets><sub><offsets xml_i="19104" xml_f="19105" txt_i="9352" txt_f="9353">3</offsets></sub><offsets xml_i="19111" xml_f="19138" txt_i="9353" txt_f="9380"> 20-30 ng/ml (Insufficient)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19187" xml_f="19196" txt_i="9381" txt_f="9390">46 (34.8)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19245" xml_f="19254" txt_i="9391" txt_f="9400">54 (42.5)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19310" xml_f="19317" txt_i="9401" txt_f="9408">25(OH)D</offsets><sub><offsets xml_i="19322" xml_f="19323" txt_i="9408" txt_f="9409">3</offsets></sub><offsets xml_i="19329" xml_f="19355" txt_i="9409" txt_f="9432"> &lt; 20 ng/ml (Deficient)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19404" xml_f="19411" txt_i="9433" txt_f="9440">70 (53)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19460" xml_f="19466" txt_i="9441" txt_f="9447">51(41)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19522" xml_f="19548" txt_i="9448" txt_f="9474">Chest X-Ray Classification</offsets><sup><offsets xml_i="19553" xml_f="19554" txt_i="9474" txt_f="9475">1</offsets></sup><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19609" xml_f="19610" txt_i="9476" txt_f="9477"> </offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19659" xml_f="19660" txt_i="9478" txt_f="9479"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19716" xml_f="19743" txt_i="9480" txt_f="9507"> Minimally Advanced disease</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19792" xml_f="19800" txt_i="9508" txt_f="9516">10 (7.6)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19849" xml_f="19858" txt_i="9517" txt_f="9526">13 (10.2)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="19914" xml_f="19942" txt_i="9527" txt_f="9555"> Moderately Advanced disease</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="19991" xml_f="20000" txt_i="9556" txt_f="9565">77 (58.3)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20049" xml_f="20058" txt_i="9566" txt_f="9575">62 (48.8)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="20114" xml_f="20135" txt_i="9576" txt_f="9597"> Far Advanced disease</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20184" xml_f="20193" txt_i="9598" txt_f="9607">45 (34.1)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20242" xml_f="20251" txt_i="9608" txt_f="9617">52 (40.9)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="20307" xml_f="20317" txt_i="9618" txt_f="9628"> No Cavity</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20366" xml_f="20373" txt_i="9629" txt_f="9636">7 (5.3)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20422" xml_f="20429" txt_i="9637" txt_f="9644">4 (3.1)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="20485" xml_f="20507" txt_i="9645" txt_f="9664"> Cavity size &lt; 4 cm</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20556" xml_f="20565" txt_i="9665" txt_f="9674">60 (45.5)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20614" xml_f="20623" txt_i="9675" txt_f="9684">59 (46.5)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="20679" xml_f="20698" txt_i="9685" txt_f="9704"> Cavity size ≥ 4 cm</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20747" xml_f="20756" txt_i="9705" txt_f="9714">65 (49.2)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20805" xml_f="20814" txt_i="9715" txt_f="9724">64 (50.4)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="20870" xml_f="20893" txt_i="9725" txt_f="9748"> No. of zones involved </offsets><sup><offsets xml_i="20898" xml_f="20899" txt_i="9748" txt_f="9749">3</offsets></sup><offsets xml_i="20905" xml_f="20916" txt_i="9749" txt_f="9760">, Mean ± SD</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="20965" xml_f="20976" txt_i="9761" txt_f="9772">3.61 ± 1.40</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21025" xml_f="21036" txt_i="9773" txt_f="9784">3.64 ± 1.48</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="21092" xml_f="21126" txt_i="9785" txt_f="9819">Sputum microbial load (microscopy)</offsets><sup><offsets xml_i="21131" xml_f="21132" txt_i="9819" txt_f="9820">2</offsets></sup><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21187" xml_f="21188" txt_i="9821" txt_f="9822"> </offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21237" xml_f="21238" txt_i="9823" txt_f="9824"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="21294" xml_f="21319" txt_i="9825" txt_f="9850">Scant, 1–9 AFB/100 fields</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21368" xml_f="21375" txt_i="9851" txt_f="9858">4 (3.0)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21424" xml_f="21431" txt_i="9859" txt_f="9866">2 (1.6)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="21487" xml_f="21513" txt_i="9867" txt_f="9893"> +1, 10–99 AFB/100 fields,</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21562" xml_f="21571" txt_i="9894" txt_f="9903">36 (27.3)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21620" xml_f="21629" txt_i="9904" txt_f="9913">34 (26.8)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="21685" xml_f="21709" txt_i="9914" txt_f="9938"> +2, 1–10 AFB/50 fields,</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21758" xml_f="21767" txt_i="9939" txt_f="9948">25 (18.9)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21816" xml_f="21825" txt_i="9949" txt_f="9958">23 (18.1)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="21881" xml_f="21907" txt_i="9959" txt_f="9982"> +3, &gt;10 AFB/20 fields,</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="21956" xml_f="21965" txt_i="9983" txt_f="9992">67 (50.8)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22014" xml_f="22023" txt_i="9993" txt_f="10002">68 (53.5)</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><italic><offsets xml_i="22087" xml_f="22099" txt_i="10003" txt_f="10015">IFN-g levels</offsets></italic><offsets xml_i="22108" xml_f="22126" txt_i="10015" txt_f="10033"> (pg/ml) mean ± SD</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22175" xml_f="22176" txt_i="10034" txt_f="10035"> </offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22225" xml_f="22226" txt_i="10036" txt_f="10037"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="22282" xml_f="22301" txt_i="10038" txt_f="10057">Unstimulated levels</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22350" xml_f="22359" txt_i="10058" txt_f="10067">0.2 ± 2.6</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22408" xml_f="22412" txt_i="10068" txt_f="10072">0 ±0</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="22468" xml_f="22484" txt_i="10073" txt_f="10089">ESAT6-stimulated</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22533" xml_f="22541" txt_i="10090" txt_f="10098">413 ±977</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="22590" xml_f="22598" txt_i="10099" txt_f="10107">303 ±804</offsets><hr></hr></td></tr><tr><td align="left"><offsets xml_i="22638" xml_f="22653" txt_i="10108" txt_f="10123">MTBs-stimulated</offsets></td><td align="center"><offsets xml_i="22677" xml_f="22687" txt_i="10124" txt_f="10134">2826 ±1391</offsets></td><td align="center"><offsets xml_i="22711" xml_f="22721" txt_i="10135" txt_f="10145">2858 ±1337</offsets></td></tr></tbody></table><table-wrap-foot><p><italic><offsets xml_i="22775" xml_f="22779" txt_i="10146" txt_f="10150">MUAC</offsets></italic><offsets xml_i="22788" xml_f="22818" txt_i="10150" txt_f="10180"> Mid Upper Arm Circumference; </offsets><italic><offsets xml_i="22826" xml_f="22829" txt_i="10180" txt_f="10183">BMI</offsets></italic><offsets xml_i="22838" xml_f="22866" txt_i="10183" txt_f="10211"> Body Mass Index; s-25-(OH)D</offsets><sub><offsets xml_i="22871" xml_f="22872" txt_i="10211" txt_f="10212">3</offsets></sub><offsets xml_i="22878" xml_f="22907" txt_i="10212" txt_f="10241"> = serum 25- hydroxyvitamin D</offsets><sub><offsets xml_i="22912" xml_f="22913" txt_i="10241" txt_f="10242">3</offsets></sub><offsets xml_i="22919" xml_f="22949" txt_i="10242" txt_f="10272">.* Severity Class (TB score)
[</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="22981" xml_f="22983" txt_i="10272" txt_f="10274">10</offsets></xref><offsets xml_i="22990" xml_f="22992" txt_i="10274" txt_f="10276">];</offsets><sup><offsets xml_i="22997" xml_f="22998" txt_i="10276" txt_f="10277">1</offsets></sup><offsets xml_i="23004" xml_f="23203" txt_i="10277" txt_f="10476">Chest X ray classification: Each hemi-lung was divided into 3 zones (total 6 lung zones): active parenchymal and cavitary disease, exclusive of old fibrotic scarring, recorded as ‘zone involvement’
[</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="23235" xml_f="23237" txt_i="10476" txt_f="10478">11</offsets></xref><offsets xml_i="23244" xml_f="23245" txt_i="10478" txt_f="10479">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="23277" xml_f="23279" txt_i="10479" txt_f="10481">12</offsets></xref><offsets xml_i="23286" xml_f="23289" txt_i="10481" txt_f="10484">]. </offsets><sup><offsets xml_i="23294" xml_f="23295" txt_i="10484" txt_f="10485">2</offsets></sup><offsets xml_i="23301" xml_f="23473" txt_i="10485" txt_f="10657">Diagnostic Standards and Classification of Tuberculosis, National Tuberculosis Association of the USA, 1961. Data are presented here as number (%), unless stated otherwise.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="23511" xml_f="23743" txt_i="10658" txt_f="10887">At each follow up visit patients were asked about symptoms of hypercalcemia i.e. nausea, vomiting, abdominal pain, confusion or renal colic. Calcium (and albumin in patients with BMI &lt; 18) was measured at 12 weeks from enrolment.</offsets></p></sec><sec><title><offsets xml_i="23765" xml_f="23805" txt_i="10889" txt_f="10929">Whole blood assay and IFN-g measurements</offsets></title><p><offsets xml_i="23816" xml_f="23890" txt_i="10930" txt_f="11004">Recombinant antigen early secreted and activated target (ESAT) -6 kDa and </offsets><italic><offsets xml_i="23898" xml_f="23913" txt_i="11004" txt_f="11019">M. tuberculosis</offsets></italic><offsets xml_i="23922" xml_f="24585" txt_i="11019" txt_f="11682"> H37Rv whole sonicate (MTBs) were provided through the NIH tuberculosis vaccine testing and reagent material contract (NO1-A1-40091) awarded to Colorado State University, USA. Mycobacterial antigen stimulated responses in study subjects of the placebo group (n = 127) and vitamin D intervention group (n = 132) were tested at the time of recruitment prior to any anti-tuberculosis treatment or supplementation and subsequently after treatment (weeks 12 of inclusion). Diluted whole blood cells were stimulated with 5 mcg/ml ESAT6 and 10 mcg/ml MTBs and IFN-g was measured in cell culture supernatants collected at 6 days post-stimulation as described previously
[</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="24617" xml_f="24619" txt_i="11682" txt_f="11684">13</offsets></xref><offsets xml_i="24626" xml_f="24768" txt_i="11684" txt_f="11826">]. All samples were set up in replicates. Samples were centrifuged to collect any cellular debris, aliquoted and stored at −70 C until tested.</offsets></p><p><offsets xml_i="24775" xml_f="25030" txt_i="11827" txt_f="12082">IFN-g was detected in cellular supernatants by using standards and ELISA reagents obtained from Endogen (Rockford, IL, USA). Cytokines were measured using a sandwich ELISA technique according to the manufacturer’s instructions and as reported previously
[</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="25062" xml_f="25064" txt_i="12082" txt_f="12084">13</offsets></xref><offsets xml_i="25071" xml_f="25188" txt_i="12084" txt_f="12201">]. Recombinant human cytokine was used to obtain a dose response curve with a range of detection from 3.9-1000 pg/ml.</offsets></p></sec><sec><title><offsets xml_i="25210" xml_f="25228" txt_i="12203" txt_f="12221">Biochemical assays</offsets></title><p><offsets xml_i="25239" xml_f="25299" txt_i="12222" txt_f="12282">Serum 25-hydroxy25-hydroxyvitamin D3 was measured using the </offsets><bold><offsets xml_i="25305" xml_f="25306" txt_i="12282" txt_f="12283">e</offsets></bold><offsets xml_i="25313" xml_f="25319" txt_i="12283" txt_f="12289">lectro</offsets><bold><offsets xml_i="25325" xml_f="25326" txt_i="12289" txt_f="12290">c</offsets></bold><offsets xml_i="25333" xml_f="25337" txt_i="12290" txt_f="12294">hemi</offsets><bold><offsets xml_i="25343" xml_f="25344" txt_i="12294" txt_f="12295">l</offsets></bold><offsets xml_i="25351" xml_f="25363" txt_i="12295" txt_f="12307">uminescence </offsets><bold><offsets xml_i="25369" xml_f="25370" txt_i="12307" txt_f="12308">i</offsets></bold><offsets xml_i="25377" xml_f="25382" txt_i="12308" txt_f="12313">mmuno</offsets><bold><offsets xml_i="25388" xml_f="25389" txt_i="12313" txt_f="12314">a</offsets></bold><offsets xml_i="25396" xml_f="25658" txt_i="12314" txt_f="12576">ssay “ECLIA” (Roche Diagnostics GmbH, D-68298 Mannheim). Serum calcium and albumin was measured by colorimetric assay (Roche Diagnostics GmbH, D-68298 Mannheim) and colorimetric determination of serum albumin using bromocresol green at pH 4.20 (Merck, Pakistan).</offsets></p><p><offsets xml_i="25665" xml_f="26039" txt_i="12577" txt_f="12951">Clinical assessments and sputum microscopic examinations were performed at 0, 4, 8 and 12 weeks of therapy. Chest radiographs and blood samples for cytokine assays were obtained at 0 and 12 weeks. At each follow up visit patients were asked about symptoms of hypercalcemia i.e. nausea, vomiting, abdominal pain, confusion or renal colic. Serum 25-hydroxy 25-hydroxyvitamin D</offsets><sub><offsets xml_i="26044" xml_f="26045" txt_i="12951" txt_f="12952">3</offsets></sub><offsets xml_i="26051" xml_f="26331" txt_i="12952" txt_f="13229">, calcium (and albumin in patients with BMI &lt; 18) were measured at 12 weeks from enrolment. For the sample size calculation, we hypothesized that vitamin D supplementation could result in a weight gain equal to or greater than 10% of the mean weight gain in the placebo group
[</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="26362" xml_f="26363" txt_i="13229" txt_f="13230">8</offsets></xref><offsets xml_i="26370" xml_f="26722" txt_i="13230" txt_f="13582">] and a 15% difference in radiographic improvement between the 2 groups. We estimated we would need 125 patients in each arm to reject the null hypothesis with a power of 80 percent and a 5% level of significance. We estimated a 15% risk of hypercalcemia after supplementation in the 25-hydroxyvitamin D arm, based on a previous study by Wejse et al.
[</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="26753" xml_f="26754" txt_i="13582" txt_f="13583">9</offsets></xref><offsets xml_i="26761" xml_f="27302" txt_i="13583" txt_f="14124">] and therefore estimated we would need 60 patients in each group for a power of 80% and 5% level of significance. The primary outcome variable was differences in weight gained and resolution of chest radiographic abnormalities. Secondary outcomes were differences in IFN-g responses, differences in sputum conversion rates and improvements in TB score. An ad hoc analysis looked at differences in the cytokine response and clinical recovery in groups stratified as ‘Optimal’, ‘Insufficient’ and ‘Deficient’ by vitamin D levels at enrolment.</offsets></p></sec><sec><title><offsets xml_i="27324" xml_f="27332" txt_i="14126" txt_f="14134">Analysis</offsets></title><p><offsets xml_i="27343" xml_f="27573" txt_i="14135" txt_f="14365">Data was analysed by ‘intention-to-treat’ analysis. Outcome variables were reported by either their means or medians and with ranges or standard deviations. Statistical comparisons at 0 and 12 weeks were performed using Student’s </offsets><italic><offsets xml_i="27581" xml_f="27582" txt_i="14365" txt_f="14366">t</offsets></italic><offsets xml_i="27591" xml_f="27863" txt_i="14366" txt_f="14638">-test for continuous variables and Pearson Chi-squared tests for categorical variables. IFN-g responses pre- and post-treatment between baseline 25-(OH)hydroxy vitamin D levels and TB severity groups were compared using the Kruskal-Wallis non-parametric test. A two-sided </offsets><italic><offsets xml_i="27871" xml_f="27872" txt_i="14638" txt_f="14639">p</offsets></italic><offsets xml_i="27881" xml_f="28183" txt_i="14639" txt_f="14938"> value of &lt; 0.05 was considered significant. Data was analysed using SPSS version 17.0. An interim safety analysis looking for differences in mortality was carried out with the institutional research office at 3 months. No differences in mortality rates were identified between the two study groups.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="28230" xml_f="28237" txt_i="14941" txt_f="14948">Results</offsets></title><sec><title><offsets xml_i="28257" xml_f="28281" txt_i="14949" txt_f="14973">Description of the study</offsets></title><p><offsets xml_i="28292" xml_f="28535" txt_i="14974" txt_f="15217">Three hundred and thirty seven patients were screened for eligibility; 259 patients were enrolled and randomized to the 2 treatment arms; 132 in the 25-hydroxyvitamin D supplementation arm and 127 in the placebo arm, as illustrated in Figure 
</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="28565" xml_f="28566" txt_i="15217" txt_f="15218">1</offsets></xref><offsets xml_i="28573" xml_f="29157" txt_i="15218" txt_f="15802">. The study was conducted from October 2009 to July 2010 with enrolment of the first participant in October 2009 and last participant in April 2010. One hundred and nineteen patients in each arm completed the study with a default/dropout rate of 8.1%. Three patients died during the study period; 2 in the 25-hydroxyvitamin D intervention arm and 1 in the placebo. Deaths in the vitamin D arm included 1 due to rapidly progressive respiratory failure of undetermined etiology within 2 weeks of inclusion and 1 in an automobile accident. One patient died of malaria in the placebo arm.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="29198" xml_f="29206" txt_i="15803" txt_f="15811">Figure 1</offsets></label><caption><p><bold><offsets xml_i="29232" xml_f="29248" txt_i="15811" txt_f="15827">Study Flowchart.</offsets></bold><offsets xml_i="29255" xml_f="29356" txt_i="15827" txt_f="15928"> Study Drug (Cholecalciferol) and Placebo (Normal Saline) matched for colour and volume of contents. </offsets><sup><offsets xml_i="29361" xml_f="29362" txt_i="15928" txt_f="15929">2</offsets></sup><offsets xml_i="29368" xml_f="29853" txt_i="15929" txt_f="16414"> ‘Completed treatment’; administration of 2 doses of study drug/placebo (over first 2 months), with follow up assessments complete at all visits over a total duration of 3 months. * Includes all patients who completed treatment at end of 3 months, as well as those who died during, or defaulted from, treatment before completion (indicated for each treatment arm). Flow Diagram adapted from the CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials.</offsets></p></caption><graphic xlink:href="1471-2334-13-22-1"></graphic></fig></sec><sec><title><offsets xml_i="29941" xml_f="29955" txt_i="16416" txt_f="16430">Study findings</offsets></title><p><offsets xml_i="29966" xml_f="30038" txt_i="16431" txt_f="16503">Baseline characteristics of the 2 study populations are shown in Table 
</offsets><xref ref-type="table" rid="T1"><offsets xml_i="30070" xml_f="30071" txt_i="16503" txt_f="16504">1</offsets></xref><offsets xml_i="30078" xml_f="30203" txt_i="16504" txt_f="16629">. The two arms did not differ significantly except for a higher number of patients with fever in the placebo arm, 49 v/s 68 (</offsets><italic><offsets xml_i="30211" xml_f="30212" txt_i="16629" txt_f="16630">p</offsets></italic><offsets xml_i="30221" xml_f="30615" txt_i="16630" txt_f="17024"> 0.008). Mean age for the total population was 28 ± 13.6 years and 135 subjects (49.5%) had + 3 AFB on sputum smear microscopy. Mean 25-hydroxyvitamin D levels for the entire population were in the ‘Insufficient’ range; 21.3 ng/mL ± 9.78. 25 hydroxyvitamin D levels were noted to be lower in patients with greater severity of chest radiographic involvement at baseline [216 (83%) v/s 43 (16%), </offsets><italic><offsets xml_i="30623" xml_f="30624" txt_i="17024" txt_f="17025">p</offsets></italic><offsets xml_i="30633" xml_f="30706" txt_i="17025" txt_f="17095"> 0.012], in females [67 (56.7%) v/s 49 (34.7%) had levels &lt; 20 ng/mL, </offsets><italic><offsets xml_i="30714" xml_f="30715" txt_i="17095" txt_f="17096">p</offsets></italic><offsets xml_i="30724" xml_f="30757" txt_i="17096" txt_f="17129"> 0.001] and in younger patients [</offsets><italic><offsets xml_i="30765" xml_f="30766" txt_i="17129" txt_f="17130">p</offsets></italic><offsets xml_i="30775" xml_f="30888" txt_i="17130" txt_f="17243"> 0.004]. There were no significant associations between baseline 25-hydroxyvitamin D levels and sputum AFB load (</offsets><italic><offsets xml_i="30896" xml_f="30897" txt_i="17243" txt_f="17244">p</offsets></italic><offsets xml_i="30906" xml_f="30936" txt_i="17244" txt_f="17274"> 0.77), or TB severity score (</offsets><italic><offsets xml_i="30944" xml_f="30945" txt_i="17274" txt_f="17275">p</offsets></italic><offsets xml_i="30954" xml_f="31055" txt_i="17275" txt_f="17376"> 0.26). There was a trend towards greater association of haemoptysis with lower levels of vitamin D (</offsets><italic><offsets xml_i="31063" xml_f="31064" txt_i="17376" txt_f="17377">p</offsets></italic><offsets xml_i="31073" xml_f="31081" txt_i="17377" txt_f="17385"> 0.049).</offsets></p><p><offsets xml_i="31088" xml_f="31189" txt_i="17386" txt_f="17487">Changes in measured clinical variables after 12 weeks of antituberculous therapy are shown in Table 
</offsets><xref ref-type="table" rid="T2"><offsets xml_i="31221" xml_f="31222" txt_i="17487" txt_f="17488">2</offsets></xref><offsets xml_i="31229" xml_f="31321" txt_i="17488" txt_f="17580">. Changes in serum 25 hydroxyvitamin D levels in the two groups is shown in Additional file
</offsets><xref ref-type="supplementary-material" rid="S1"><offsets xml_i="31370" xml_f="31371" txt_i="17580" txt_f="17581">1</offsets></xref><offsets xml_i="31378" xml_f="31580" txt_i="17581" txt_f="17783">: Figure S1. After 12 weeks of antituberculous therapy, the 25-hydroxyvitamin D supplemented arm had a mean weight gain (kg) of; + 3.75 (3.16 – 4.34) v/s + 2.61 (95% CI 1.99 – 3.23) in the placebo arm (</offsets><italic><offsets xml_i="31588" xml_f="31589" txt_i="17783" txt_f="17784">p</offsets></italic><offsets xml_i="31598" xml_f="31698" txt_i="17784" txt_f="17884"> 0.009) and in BMI; + 1.39 (95% CI 1.15 – 1.63) v/s + 0.95 (95% CI 0.71 – 1.19) in the placebo arm (</offsets><italic><offsets xml_i="31706" xml_f="31707" txt_i="17884" txt_f="17885">p</offsets></italic><offsets xml_i="31716" xml_f="31884" txt_i="17885" txt_f="18053"> 0.01). Interpretation of chest radiographs at 12 weeks showed that the mean number of zones involved in the vitamin D arm were 1.35 v/s 1.82 zones in the placebo arm (</offsets><italic><offsets xml_i="31892" xml_f="31893" txt_i="18053" txt_f="18054">p</offsets></italic><offsets xml_i="31902" xml_f="32050" txt_i="18054" txt_f="18202"> 0.004) (95% CI 0.15, 0.79). 106 (89.8%) patients in the vitamin D arm had 50% or more reduction in cavity size v/s 111 (94.8%) in the placebo arm (</offsets><italic><offsets xml_i="32058" xml_f="32059" txt_i="18202" txt_f="18203">p</offsets></italic><offsets xml_i="32068" xml_f="32076" txt_i="18203" txt_f="18211"> 0.035).</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="32124" xml_f="32131" txt_i="18212" txt_f="18219">Table 2</offsets></label><caption><p><offsets xml_i="32151" xml_f="32223" txt_i="18219" txt_f="18291">Changes in measured clinical variables from baseline to study completion</offsets></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead><tr><th align="left" valign="bottom"><bold><offsets xml_i="32458" xml_f="32487" txt_i="18292" txt_f="18321">Measured disease parameter(s)</offsets></bold><hr></hr></th><th colspan="2" align="center" valign="bottom"><bold><offsets xml_i="32561" xml_f="32574" txt_i="18321" txt_f="18334">Randomization</offsets></bold><hr></hr></th><th align="center" valign="bottom"><bold><italic><offsets xml_i="32644" xml_f="32645" txt_i="18334" txt_f="18335">p</offsets></italic></bold><bold><offsets xml_i="32667" xml_f="32682" txt_i="18335" txt_f="18350">-value (95% CI)</offsets></bold><hr></hr></th></tr><tr><th align="left"><offsets xml_i="32729" xml_f="32730" txt_i="18350" txt_f="18351"> </offsets></th><th align="center"><bold><offsets xml_i="32760" xml_f="32787" txt_i="18351" txt_f="18378">Drug intervention (n = 132)</offsets></bold></th><th align="center"><bold><offsets xml_i="32824" xml_f="32854" txt_i="18378" txt_f="18408">Placebo intervention (n = 127)</offsets></bold></th><th align="center"><offsets xml_i="32885" xml_f="32886" txt_i="18408" txt_f="18409"> </offsets></th></tr></thead><tbody><tr><td colspan="4" align="left" valign="bottom"><bold><offsets xml_i="32966" xml_f="32999" txt_i="18409" txt_f="18442">TB Severity (clinical assessment)</offsets></bold><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="33062" xml_f="33103" txt_i="18443" txt_f="18484">Mean Δ in TB score (points) ± SD, (95 CI)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="33152" xml_f="33181" txt_i="18485" txt_f="18514">- 3.19 ± 2.37, (−3.61, -2.75)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="33230" xml_f="33259" txt_i="18515" txt_f="18544">- 2.79 ± 2.44, (−3.23, -2.34)</offsets><hr></hr></td><td align="char" valign="bottom" char="."><offsets xml_i="33315" xml_f="33320" txt_i="18545" txt_f="18550">0.198</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="33376" xml_f="33407" txt_i="18551" txt_f="18582">Mean Δ in weight (kg), (95% CI)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="33456" xml_f="33477" txt_i="18583" txt_f="18604">+ 4.02, (3.18 – 4.86)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="33526" xml_f="33547" txt_i="18605" txt_f="18626">+ 2.61, (1.99 – 3.23)</offsets><hr></hr></td><td align="char" valign="bottom" char="."><offsets xml_i="33603" xml_f="33608" txt_i="18627" txt_f="18632">0.007</offsets><hr></hr></td></tr><tr><td align="center" valign="bottom"><offsets xml_i="33666" xml_f="33689" txt_i="18633" txt_f="18656">Mean Δ in BMI, (95% CI)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="33738" xml_f="33759" txt_i="18657" txt_f="18678">+ 1.48, (1.17 – 1.78)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="33808" xml_f="33829" txt_i="18679" txt_f="18700">+ 0.96, (0.72 – 1.20)</offsets><hr></hr></td><td align="char" valign="bottom" char="."><offsets xml_i="33885" xml_f="33890" txt_i="18701" txt_f="18706">0.008</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="33946" xml_f="33975" txt_i="18707" txt_f="18736">Mean Δ in MUAC (cm), (95% CI)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="34024" xml_f="34045" txt_i="18737" txt_f="18758">+ 1.34, (0.74 – 1.64)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="34094" xml_f="34115" txt_i="18759" txt_f="18780">+ 0.97, (0.68 – 1.26)</offsets><hr></hr></td><td align="char" valign="bottom" char="."><offsets xml_i="34171" xml_f="34176" txt_i="18781" txt_f="18786">0.079</offsets><hr></hr></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold><offsets xml_i="34250" xml_f="34273" txt_i="18787" txt_f="18810">Chest X-Ray Involvement</offsets></bold><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="34336" xml_f="34353" txt_i="18811" txt_f="18828">Mean no. of zones</offsets><sup><offsets xml_i="34358" xml_f="34359" txt_i="18828" txt_f="18829">1</offsets></sup><offsets xml_i="34365" xml_f="34379" txt_i="18829" txt_f="18843"> involved ± SD</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="34428" xml_f="34439" txt_i="18844" txt_f="18855">1.35 ± 1.13</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="34488" xml_f="34499" txt_i="18856" txt_f="18867">1.82 ± 1.35</offsets><hr></hr></td><td align="char" valign="bottom" char="."><offsets xml_i="34555" xml_f="34560" txt_i="18868" txt_f="18873">0.004</offsets><hr></hr></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold><offsets xml_i="34634" xml_f="34646" txt_i="18874" txt_f="18886">Sputum Smear</offsets></bold><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="34709" xml_f="34735" txt_i="18887" txt_f="18913">Smear Conversion, no. (%) </offsets><sup><offsets xml_i="34740" xml_f="34741" txt_i="18913" txt_f="18914">2</offsets></sup><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="34796" xml_f="34806" txt_i="18915" txt_f="18925">108 (81.8)</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="34855" xml_f="34865" txt_i="18926" txt_f="18936">103 (81.1)</offsets><hr></hr></td><td align="char" valign="bottom" char="."><offsets xml_i="34921" xml_f="34925" txt_i="18937" txt_f="18941">0.39</offsets><hr></hr></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold><offsets xml_i="34999" xml_f="35029" txt_i="18942" txt_f="18972">IFN-g levels (pg/ml) mean ± SD</offsets></bold><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="35092" xml_f="35111" txt_i="18973" txt_f="18992">Unstimulated levels</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="35160" xml_f="35169" txt_i="18993" txt_f="19002">3.9 ±28.7</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="35218" xml_f="35228" txt_i="19003" txt_f="19013">4.3 ± 45.2</offsets><hr></hr></td><td align="char" valign="bottom" char="."><offsets xml_i="35284" xml_f="35289" txt_i="19014" txt_f="19019">0.325</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="35345" xml_f="35362" txt_i="19020" txt_f="19037">ESAT6-stimulated*</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="35411" xml_f="35419" txt_i="19038" txt_f="19046">387 ±920</offsets><hr></hr></td><td align="center" valign="bottom"><offsets xml_i="35468" xml_f="35476" txt_i="19047" txt_f="19055">206 ±665</offsets><hr></hr></td><td align="char" valign="bottom" char="."><offsets xml_i="35532" xml_f="35537" txt_i="19056" txt_f="19061">0.077</offsets><hr></hr></td></tr><tr><td align="left"><offsets xml_i="35577" xml_f="35593" txt_i="19062" txt_f="19078">MTBs-stimulated*</offsets></td><td align="center"><offsets xml_i="35617" xml_f="35627" txt_i="19079" txt_f="19089">3092 ±1363</offsets></td><td align="center"><offsets xml_i="35651" xml_f="35661" txt_i="19090" txt_f="19100">2987 ±1510</offsets></td><td align="char" char="."><offsets xml_i="35692" xml_f="35697" txt_i="19101" txt_f="19106">0.497</offsets></td></tr></tbody></table><table-wrap-foot><p><italic><offsets xml_i="35751" xml_f="35755" txt_i="19107" txt_f="19111">MUAC</offsets></italic><offsets xml_i="35764" xml_f="35794" txt_i="19111" txt_f="19141"> Mid Upper Arm Circumference; </offsets><italic><offsets xml_i="35802" xml_f="35805" txt_i="19141" txt_f="19144">BMI</offsets></italic><offsets xml_i="35814" xml_f="35835" txt_i="19144" txt_f="19165"> Body Mass Index; 95 </offsets><italic><offsets xml_i="35843" xml_f="35845" txt_i="19165" txt_f="19167">CI</offsets></italic><offsets xml_i="35854" xml_f="35880" txt_i="19167" txt_f="19193"> 95% Confidence Interval; </offsets><italic><offsets xml_i="35888" xml_f="35890" txt_i="19193" txt_f="19195">SD</offsets></italic><offsets xml_i="35899" xml_f="35962" txt_i="19195" txt_f="19258"> Standard Deviation; s-25-(OH) D3 = serum 25-hydroxyvitamin D3.</offsets></p><p><sup><offsets xml_i="35974" xml_f="35975" txt_i="19259" txt_f="19260">1</offsets></sup><offsets xml_i="35981" xml_f="36156" txt_i="19260" txt_f="19435"> Division of bilateral ling fields into a total of 6 zones (3 per each lung, ‘zone involvement’ = active parenchymal and cavitary disease, exclusive of old fibrotic scarring. </offsets><sup><offsets xml_i="36161" xml_f="36162" txt_i="19435" txt_f="19436">2</offsets></sup><offsets xml_i="36168" xml_f="36366" txt_i="19436" txt_f="19634"> Includes all patients who were expectorating at baseline, and claimed ‘unable to expectorate’ at completion of treatment 12 weeks later. ESAT6 early secreted and T cell activated antigen-6 kDa; MTB</offsets><sub><offsets xml_i="36371" xml_f="36372" txt_i="19634" txt_f="19635">s</offsets></sub><offsets xml_i="36378" xml_f="36429" txt_i="19635" txt_f="19686"> Mycobacterium tuberculosis whole sonicate antigen.</offsets></p><p><offsets xml_i="36436" xml_f="36517" txt_i="19687" txt_f="19768">*Denotes cytokine levels after subtraction of background from unstimulated cells.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="36555" xml_f="36795" txt_i="19769" txt_f="20009">Evaluation of sputum microscopy data for the study subjects showed that 134 (60%) patients were sputum smear negative by week 4 of therapy. Overall, no significant differences were observed in sputum smear conversion rates (Additional file
</offsets><xref ref-type="supplementary-material" rid="S2"><offsets xml_i="36844" xml_f="36845" txt_i="20009" txt_f="20010">2</offsets></xref><offsets xml_i="36852" xml_f="36890" txt_i="20010" txt_f="20048">: Figure S2) or TB scores at weeks 4 (</offsets><italic><offsets xml_i="36898" xml_f="36899" txt_i="20048" txt_f="20049">p</offsets></italic><offsets xml_i="36908" xml_f="36919" txt_i="20049" txt_f="20060"> 0.18), 8 (</offsets><italic><offsets xml_i="36927" xml_f="36928" txt_i="20060" txt_f="20061">p</offsets></italic><offsets xml_i="36937" xml_f="36952" txt_i="20061" txt_f="20076"> 0.89) and 12 (</offsets><italic><offsets xml_i="36960" xml_f="36961" txt_i="20076" txt_f="20077">p</offsets></italic><offsets xml_i="36970" xml_f="37263" txt_i="20077" txt_f="20367"> 0.16) between the 2 study arms. On post hoc analysis, patients in the vitamin D arm and serum &lt; 30 ng/mL (‘Insufficient’ and ‘Deficient’ groups) at enrolment had significantly greater improvements in TB severity scores compared to patients with normal baseline 25-hydroxyvitamin D levels; </offsets><italic><offsets xml_i="37271" xml_f="37272" txt_i="20367" txt_f="20368">p</offsets></italic><offsets xml_i="37281" xml_f="37458" txt_i="20368" txt_f="20545"> 0.014. Additionally, the subgroup in the supplementation arm that had baseline ‘Insufficient’ levels showed a trend towards lower number of zones involved on chest radiograph (</offsets><italic><offsets xml_i="37466" xml_f="37467" txt_i="20545" txt_f="20546">p</offsets></italic><offsets xml_i="37476" xml_f="37519" txt_i="20546" txt_f="20589"> 0.054) and higher sputum smear clearance (</offsets><italic><offsets xml_i="37527" xml_f="37528" txt_i="20589" txt_f="20590">p</offsets></italic><offsets xml_i="37537" xml_f="37603" txt_i="20590" txt_f="20656"> 0.05) however, this difference was not statistically significant.</offsets></p></sec><sec><title><offsets xml_i="37625" xml_f="37705" txt_i="20658" txt_f="20738">Mycobacterial-antigen stimulated IFN-g responses in placebo and treatment groups</offsets></title><p><offsets xml_i="37716" xml_f="38126" txt_i="20739" txt_f="21149">We first determined mycobacterial antigen-stimulated IFN-g responses at baseline in the placebo group to investigate possible effects in cytokine secretion profiles due to variations in disease severity in patients. We observed that ESAT6- induced IFN-g responses did not differ between patients classified according to their TB scores into Class I, II and III disease (p = 0.996, Kruskal-Wallis test, Figure 
</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="38156" xml_f="38157" txt_i="21149" txt_f="21150">2</offsets></xref><offsets xml_i="38164" xml_f="38174" txt_i="21150" txt_f="21160">A). Also, </offsets><italic><offsets xml_i="38182" xml_f="38197" txt_i="21160" txt_f="21175">M. tuberculosis</offsets></italic><offsets xml_i="38206" xml_f="38340" txt_i="21175" txt_f="21309"> sonicate (MTBs) – induced IFN-g was similar between patients of with Class I, II and III TB (p = 0.257, Kruskal-Wallis test, Figure 
</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="38370" xml_f="38371" txt_i="21309" txt_f="21310">2</offsets></xref><offsets xml_i="38378" xml_f="38381" txt_i="21310" txt_f="21313">B).</offsets></p><fig id="F2" position="float"><label><offsets xml_i="38422" xml_f="38430" txt_i="21314" txt_f="21322">Figure 2</offsets></label><caption><p><bold><offsets xml_i="38456" xml_f="38593" txt_i="21322" txt_f="21459">Mycobacterial-antigen stimulated IFN-g responses in TB patients according to disease severity and circulating 25-hydroxyvitamin D levels.</offsets></bold><offsets xml_i="38600" xml_f="38658" txt_i="21459" txt_f="21517"> Diluted whole blood cells were stimulated with ESAT6 and </offsets><italic><offsets xml_i="38666" xml_f="38681" txt_i="21517" txt_f="21532">M. tuberculosis</offsets></italic><offsets xml_i="38690" xml_f="38873" txt_i="21532" txt_f="21715"> sonicate (MTBs) and IFN-g measured in cell supernatants after 6 days of culture. The graphs depict IFN-g responses in patients classified into severity according to their TB scores (</offsets><bold><offsets xml_i="38879" xml_f="38882" txt_i="21715" txt_f="21718">a-b</offsets></bold><offsets xml_i="38889" xml_f="39016" txt_i="21718" txt_f="21845">); Severity Class I (TB score 0 to 5), Class II (TB score 6 – 7) and Class III (TB score ≥ 8) in response to stimulation with (</offsets><bold><offsets xml_i="39022" xml_f="39023" txt_i="21845" txt_f="21846">a</offsets></bold><offsets xml_i="39030" xml_f="39043" txt_i="21846" txt_f="21859">) ESAT6 and (</offsets><bold><offsets xml_i="39049" xml_f="39050" txt_i="21859" txt_f="21860">b</offsets></bold><offsets xml_i="39057" xml_f="39105" txt_i="21860" txt_f="21908">) MTBs, or according to their vitamin D levels (</offsets><bold><offsets xml_i="39111" xml_f="39114" txt_i="21908" txt_f="21911">c-d</offsets></bold><offsets xml_i="39121" xml_f="39243" txt_i="21911" txt_f="22027">); Optimal (&gt;30 nmol/ml), Insufficient (20–30 nmol/ml) or Deficient (&lt; 20 nmol/ml) in response to stimulation with (</offsets><bold><offsets xml_i="39249" xml_f="39250" txt_i="22027" txt_f="22028">c</offsets></bold><offsets xml_i="39257" xml_f="39270" txt_i="22028" txt_f="22041">) ESAT6 and (</offsets><bold><offsets xml_i="39276" xml_f="39277" txt_i="22041" txt_f="22042">d</offsets></bold><offsets xml_i="39284" xml_f="39444" txt_i="22042" txt_f="22202">) MTBs. The box and whiskers plots depict cytokine responses in the 10th to 90th percentiles with the horizontal bar indicating the median levels of each group.</offsets></p></caption><graphic xlink:href="1471-2334-13-22-2"></graphic></fig><p><offsets xml_i="39517" xml_f="39645" txt_i="22203" txt_f="22331">As study subjects had variable circulating levels of 25-hydroxyvitamin D and vitamin D suppresses IFN- γ production in the host.</offsets><sup><offsets xml_i="39650" xml_f="39651" txt_i="22331" txt_f="22332">1</offsets></sup><offsets xml_i="39657" xml_f="40147" txt_i="22332" txt_f="22822"> we classified patients into those with Optimal, Insufficient or Deficient 25-hydroxyvitamin D levels at baseline and then determined mycobacterial antigen-stimulated IFN-g responses to see if there was any association between serum 25 hydroxyvitamin D levels and IFN-g responses in the placebo group. ESAT6 stimulated whole blood cell IFN-g secretion of groups with Optimal, Insufficient or Deficient 25-hydroxyvitamin D levels did not differ (p = 0.503, Kruskal-Wallis analysis), Figure 
</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="40177" xml_f="40178" txt_i="22822" txt_f="22823">2</offsets></xref><offsets xml_i="40185" xml_f="40322" txt_i="22823" txt_f="22960">C. MTBs-induced IFN-g secretion was also comparable between the different vitamin D groups (p = 0.608, Kruskal-Wallis analysis), Figure 
</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="40352" xml_f="40353" txt_i="22960" txt_f="22961">2</offsets></xref><offsets xml_i="40360" xml_f="40362" txt_i="22961" txt_f="22963">D.</offsets></p></sec><sec><title><offsets xml_i="40384" xml_f="40495" txt_i="22965" txt_f="23076">Increased MTBs-induced IFN-g responses with supplementation in those with Deficient 25-hydroxy vitamin D levels</offsets></title><p><offsets xml_i="40506" xml_f="40845" txt_i="23077" txt_f="23416">We subsequently determined mycobacterial antigen-stimulated IFN-g responses prior to initiation of therapy (0 week) and after 12 weeks of therapy in both placebo and intervention arms of the study. It was observed that MTBs-induced IFN-g levels in the 25-hydroxyvitamin D intervention group were increased post-therapy (p = 0.022, Figure 
</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="40875" xml_f="40876" txt_i="23416" txt_f="23417">3</offsets></xref><offsets xml_i="40883" xml_f="41179" txt_i="23417" txt_f="23713">). However, no difference was observed in MTBs-induced IFN-g levels compared between 0 and 12 weeks in the placebo group. When ESAT6- stimulated IFN-g responses were considered no difference was observed between 0 and 12-week responses in either the placebo or intervention arms (Additional file
</offsets><xref ref-type="supplementary-material" rid="S3"><offsets xml_i="41228" xml_f="41229" txt_i="23713" txt_f="23714">3</offsets></xref><offsets xml_i="41236" xml_f="41248" txt_i="23714" txt_f="23726">: Table S1).</offsets></p><fig id="F3" position="float"><label><offsets xml_i="41289" xml_f="41297" txt_i="23727" txt_f="23735">Figure 3</offsets></label><caption><p><bold><offsets xml_i="41323" xml_f="41439" txt_i="23735" txt_f="23851">MTBs-induced IFN-g secretion is increased in the Vitamin D treatment arm after 12 weeks of anti-tuberculous therapy.</offsets></bold><offsets xml_i="41446" xml_f="41494" txt_i="23851" txt_f="23899"> Diluted whole blood cells were stimulated with </offsets><italic><offsets xml_i="41502" xml_f="41517" txt_i="23899" txt_f="23914">M. tuberculosis</offsets></italic><offsets xml_i="41526" xml_f="41886" txt_i="23914" txt_f="24271"> sonicate (MTBs) and IFN-g measured in cell supernatants after 6 days of culture. The box and whiskers plots depict cytokine responses in the 10th to 90th percentiles with the horizontal bar indicating the median levels of each group. ‘*' Denotes values significantly different p &lt; 0.05 between levels at 0 and 12 weeks respectively as determined by paired </offsets><italic><offsets xml_i="41894" xml_f="41895" txt_i="24271" txt_f="24272">t</offsets></italic><offsets xml_i="41904" xml_f="41919" txt_i="24272" txt_f="24287"> test analysis.</offsets></p></caption><graphic xlink:href="1471-2334-13-22-3"></graphic></fig><p><offsets xml_i="41992" xml_f="42314" txt_i="24288" txt_f="24610">Further, we investigated factors which may play a role in determining the increase in MTBs- stimulated IFN-g responses in the intervention group post-therapy and further analysed this data after sub-classification of patients according to disease severity and also their baseline serum level of 25-hydroxyvitamin D levels.</offsets></p></sec><sec><title><italic><offsets xml_i="42344" xml_f="42359" txt_i="24612" txt_f="24627">M. tuberculosis</offsets></italic><offsets xml_i="42368" xml_f="42485" txt_i="24627" txt_f="24744"> sonicate antigen-induced IFN-g responses are increased as a consequence of treatment in patients with more severe TB</offsets></title><p><offsets xml_i="42496" xml_f="42742" txt_i="24745" txt_f="24991">It was observed that MTBs – induced IFN- γ responses significantly increased in patients with Class III disease after 12 weeks of anti-tuberculous therapy in both the placebo (p = 0.001) and 25-hydroxyvitamin D treatment arm (p = 0.034), Figure 
</offsets><xref ref-type="fig" rid="F4"><offsets xml_i="42772" xml_f="42773" txt_i="24991" txt_f="24992">4</offsets></xref><offsets xml_i="42780" xml_f="42919" txt_i="24992" txt_f="25131">A-B. No such post-treatment increase was observed when ESAT6-induced IFN- γ responses in the study subjects were compared (Additional file
</offsets><xref ref-type="supplementary-material" rid="S4"><offsets xml_i="42968" xml_f="42969" txt_i="25131" txt_f="25132">4</offsets></xref><offsets xml_i="42976" xml_f="42988" txt_i="25132" txt_f="25144">: Table S2).</offsets></p><fig id="F4" position="float"><label><offsets xml_i="43029" xml_f="43037" txt_i="25145" txt_f="25153">Figure 4</offsets></label><caption><p><bold><offsets xml_i="43063" xml_f="43165" txt_i="25153" txt_f="25255">MTBs- stimulated IFN-g levels are increased post-therapy in TB patients with deficient more severe TB.</offsets></bold><offsets xml_i="43172" xml_f="43404" txt_i="25255" txt_f="25487"> Whole blood cells were stimulated with MTBs and IFN-g measured in cell supernatants and compared between patients classified into TB severity classes I, II and III. Responses at 0 and 12 weeks were compared in each group by paired </offsets><italic><offsets xml_i="43412" xml_f="43413" txt_i="25487" txt_f="25488">t</offsets></italic><offsets xml_i="43422" xml_f="43591" txt_i="25488" txt_f="25657"> test analysis. The box and whiskers plots depict cytokine responses in the 10th to 90th percentiles with the horizontal bar indicating the median levels of each group. </offsets><bold><offsets xml_i="43597" xml_f="43598" txt_i="25657" txt_f="25658">a</offsets></bold><offsets xml_i="43605" xml_f="43619" txt_i="25658" txt_f="25672">, Placebo arm </offsets><bold><offsets xml_i="43625" xml_f="43626" txt_i="25672" txt_f="25673">b</offsets></bold><offsets xml_i="43633" xml_f="43727" txt_i="25673" txt_f="25764">, Drug intervention arm. ‘*' Denotes p &lt;0.05 between levels at 0 and 12 weeks respectively.</offsets></p></caption><graphic xlink:href="1471-2334-13-22-4"></graphic></fig></sec><sec><title><offsets xml_i="43815" xml_f="43844" txt_i="25766" txt_f="25795">Supplementation increases in </offsets><italic><offsets xml_i="43852" xml_f="43867" txt_i="25795" txt_f="25810">M. tuberculosis</offsets></italic><offsets xml_i="43876" xml_f="43976" txt_i="25810" txt_f="25910"> sonicate induced IFN-g responses in patients with deficient 25-(OH) vitamin hydroxyvitamin D levels</offsets></title><p><offsets xml_i="43987" xml_f="44391" txt_i="25911" txt_f="26315">To investigate the effect of 25-(OH) vitamin D supplementation in patients with different serum 25-hydroxyvitamin D levels we compared subjects in both arms of the study classified into those with Optimal, Insufficient and Deficient 25-hydroxyvitamin D levels. Increase in MTBs-induced IFN-g secretion after therapy occurred only in subjects with Deficient 25-hydroxyvitamin D levels (p = 0.021, Figure 
</offsets><xref ref-type="fig" rid="F5"><offsets xml_i="44421" xml_f="44422" txt_i="26315" txt_f="26316">5</offsets></xref><offsets xml_i="44429" xml_f="44501" txt_i="26316" txt_f="26388">B) in the drug intervention group but not in the placebo group, Figure 
</offsets><xref ref-type="fig" rid="F5"><offsets xml_i="44531" xml_f="44532" txt_i="26388" txt_f="26389">5</offsets></xref><offsets xml_i="44539" xml_f="44685" txt_i="26389" txt_f="26535">A. ESAT6 induced – IFN- γ responses at 0 and 12 weeks did not differ in either the placebo or 25-hydroxyvitamin D treatment arms (Additional file
</offsets><xref ref-type="supplementary-material" rid="S5"><offsets xml_i="44734" xml_f="44735" txt_i="26535" txt_f="26536">5</offsets></xref><offsets xml_i="44742" xml_f="44754" txt_i="26536" txt_f="26548">: Table S3).</offsets></p><fig id="F5" position="float"><label><offsets xml_i="44795" xml_f="44803" txt_i="26549" txt_f="26557">Figure 5</offsets></label><caption><p><bold><offsets xml_i="44829" xml_f="44933" txt_i="26557" txt_f="26661">MTBs- stimulated IFN-g levels are increased post-therapy in TB patients with deficient Vitamin D levels.</offsets></bold><offsets xml_i="44940" xml_f="45145" txt_i="26661" txt_f="26860"> Whole blood cells were stimulated with MTBs and IFN-g measured in cell supernatants at 6 days post-stimulation. Vitamin D levels &gt;30 ng/ml, Optimal; 20–30 ng/ml, Insufficient; &lt;20 ng/nl, Deficient. </offsets><bold><offsets xml_i="45151" xml_f="45152" txt_i="26860" txt_f="26861">a</offsets></bold><offsets xml_i="45159" xml_f="45173" txt_i="26861" txt_f="26875">, Placebo arm </offsets><bold><offsets xml_i="45179" xml_f="45180" txt_i="26875" txt_f="26876">b</offsets></bold><offsets xml_i="45187" xml_f="45458" txt_i="26876" txt_f="27144">, Drug intervention arm. The box and whiskers plots depict cytokine responses in the 10th to 90th percentiles with the horizontal bar indicating the median levels of each group. ‘*' Denotes p &lt;0.05 between levels at 0 and 12 weeks respectively as determined by paired </offsets><italic><offsets xml_i="45466" xml_f="45467" txt_i="27144" txt_f="27145">t</offsets></italic><offsets xml_i="45476" xml_f="45491" txt_i="27145" txt_f="27160"> test analysis.</offsets></p></caption><graphic xlink:href="1471-2334-13-22-5"></graphic></fig></sec></sec><sec sec-type="discussion"><title><offsets xml_i="45607" xml_f="45617" txt_i="27163" txt_f="27173">Discussion</offsets></title><p><offsets xml_i="45628" xml_f="45907" txt_i="27174" txt_f="27453">We have shown that therapeutic doses of Vitamin D (in the form of 2 doses of cholecalciferol at monthly intervals), given to patients with active pulmonary TB, can lead to proportionately greater weight gain and more rapid radiographic clearing of disease as compared to placebo.</offsets></p><p><offsets xml_i="45914" xml_f="46103" txt_i="27454" txt_f="27643">It has recently been proposed that vitamin D accelerates resolution of host inflammatory responses and this may contribute to the improvement observed in vitamin D supplemented TB therapy
[</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="46135" xml_f="46137" txt_i="27643" txt_f="27645">14</offsets></xref><offsets xml_i="46144" xml_f="46356" txt_i="27645" txt_f="27857">]. Here we illustrate that vitamin D supplementation enhances mycobacterial-antigen induced IFN-g secretion in patients with Deficient 25-hydroxyvitamin D levels, thereby improving cell mediated immunity against </offsets><italic><offsets xml_i="46364" xml_f="46379" txt_i="27857" txt_f="27872">M. tuberculosis</offsets></italic><offsets xml_i="46388" xml_f="46389" txt_i="27872" txt_f="27873">.</offsets></p><p><offsets xml_i="46396" xml_f="46481" txt_i="27874" txt_f="27959">25-hydroxyvitamin D is recognized as an important immune-modulator in TB. 1, 25 (OH) </offsets><sub><offsets xml_i="46486" xml_f="46487" txt_i="27959" txt_f="27960">2</offsets></sub><offsets xml_i="46493" xml_f="46495" txt_i="27960" txt_f="27962"> D</offsets><sub><offsets xml_i="46500" xml_f="46501" txt_i="27962" txt_f="27963">3</offsets></sub><offsets xml_i="46507" xml_f="46581" txt_i="27963" txt_f="28037"> binding with VDRs activates cathelicidin-mediated mycobacterial killing
[</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="46612" xml_f="46613" txt_i="28037" txt_f="28038">1</offsets></xref><offsets xml_i="46620" xml_f="46621" txt_i="28038" txt_f="28039">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="46652" xml_f="46653" txt_i="28039" txt_f="28040">2</offsets></xref><offsets xml_i="46660" xml_f="46754" txt_i="28040" txt_f="28134">] whilst 25-hydroxyvitamin D deficiency increases the susceptibility and vulnerability to TB
[</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="46785" xml_f="46786" txt_i="28134" txt_f="28135">3</offsets></xref><offsets xml_i="46793" xml_f="46794" txt_i="28135" txt_f="28136">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="46825" xml_f="46826" txt_i="28136" txt_f="28137">4</offsets></xref><offsets xml_i="46833" xml_f="46948" txt_i="28137" txt_f="28252">]. G interferon (IFN-γ) is a proinflammatory cytokine, which plays a critical role in resistance to MTB infection
[</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="46980" xml_f="46982" txt_i="28252" txt_f="28254">15</offsets></xref><offsets xml_i="46989" xml_f="47167" txt_i="28254" txt_f="28432">]. Infection with MTB induces T lymphocytes, natural killer cells and alveolar macrophages to express IFN-g and induces IFN-γ-driven monokines that regulate granuloma formation
[</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="47199" xml_f="47201" txt_i="28432" txt_f="28434">16</offsets></xref><offsets xml_i="47208" xml_f="47308" txt_i="28434" txt_f="28534">]. IFN-g responses have been shown to be depressed in patients with advanced forms of tuberculosis
[</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="47340" xml_f="47342" txt_i="28534" txt_f="28536">17</offsets></xref><offsets xml_i="47349" xml_f="47707" txt_i="28536" txt_f="28894">]. We observed a significant improvement in MTBs-induced IFN-g responses after 12 weeks of ATT in vitamin D ‘Deficient’ patients who received 25-hydroxyvitamin. This is the first vitamin D supplementation study where groups have been stratified into those with differing disease severity and also according to their baseline serum 25-hydroxyvitamin D levels.</offsets></p><p><offsets xml_i="47714" xml_f="47862" txt_i="28895" txt_f="29043">Previous reports by Ulrichs et al. have shown that IFN-g producing cells against ESAT6 in tuberculosis patients increase post-tuberculosis therapy
[</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="47894" xml_f="47896" txt_i="29043" txt_f="29045">18</offsets></xref><offsets xml_i="47903" xml_f="48104" txt_i="29045" txt_f="29246">]. However, we were unable to demonstrate any difference in ESAT6-induced IFN- γ responses between patients prior to and post-treatment. This is in concordance with a recent report by Coussens et al.
[</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="48136" xml_f="48138" txt_i="29246" txt_f="29248">14</offsets></xref><offsets xml_i="48145" xml_f="48352" txt_i="29248" txt_f="29455">] that did not show any change in ESAT-6 induced IFN-g in patients post-antituberculous therapy. ESAT6 and culture filtrate protein 10 (CFP10) are both encoded by the region of difference 1 (RD1) present in </offsets><italic><offsets xml_i="48360" xml_f="48375" txt_i="29455" txt_f="29470">M. tuberculosis</offsets></italic><offsets xml_i="48384" xml_f="48401" txt_i="29470" txt_f="29487"> and in virulent </offsets><italic><offsets xml_i="48409" xml_f="48418" txt_i="29487" txt_f="29496">M. bovis,</offsets></italic><offsets xml_i="48427" xml_f="48444" txt_i="29496" txt_f="29513"> but absent from </offsets><italic><offsets xml_i="48452" xml_f="48460" txt_i="29513" txt_f="29521">M. bovis</offsets></italic><offsets xml_i="48469" xml_f="48506" txt_i="29521" txt_f="29558"> BCG and environmental mycobacteria
[</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="48538" xml_f="48540" txt_i="29558" txt_f="29560">19</offsets></xref><offsets xml_i="48547" xml_f="48723" txt_i="29560" txt_f="29736">]. Antigen based interferon g release assays (IGRAs) have a varied sensitivity in endemic and non-endemic settings, attributable to exposure to environmental mycobacterial and </offsets><italic><offsets xml_i="48731" xml_f="48746" txt_i="29736" txt_f="29751">M. tuberculosis</offsets></italic><offsets xml_i="48755" xml_f="48794" txt_i="29751" txt_f="29790"> and resulting T cell IFN-g responses
[</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="48826" xml_f="48828" txt_i="29790" txt_f="29792">20</offsets></xref><offsets xml_i="48835" xml_f="48838" txt_i="29792" txt_f="29795">]. </offsets><italic><offsets xml_i="48846" xml_f="48861" txt_i="29795" txt_f="29810">M. tuberculosis</offsets></italic><offsets xml_i="48870" xml_f="48929" txt_i="29810" txt_f="29869"> whole sonicate (MTBs) contains cross reactive epitopes to </offsets><italic><offsets xml_i="48937" xml_f="48945" txt_i="29869" txt_f="29877">M. bovis</offsets></italic><offsets xml_i="48954" xml_f="49270" txt_i="29877" txt_f="30193"> BCG vaccine strain and environmental mycobacteria and therefore, can induce potent cytokine responses from T cells, macrophages and other polymorphonuclear cells. MTBs induced responses have been useful in differentiating severity of disease in TB. Patients with advanced disease display decreased IFN-g responses
[</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="49302" xml_f="49304" txt_i="30193" txt_f="30195">13</offsets></xref><offsets xml_i="49311" xml_f="50665" txt_i="30195" txt_f="31546">]. We observed that after 12 weeks of ATT, the Class III severity groups had significant increases in MTBs-induced IFN-g responses. This increase in mycobacterial-antigen induced IFN-g responses represents host immunity in patients with advanced pulmonary disease, possibly leading to improved resolution of the disease. Further analysis of to determine the impact of host 25- hydroxyvitamin D levels on immune recovery revealed that in patients who received vitamin D supplementation, MTBs-induced IFN-g secretion was significantly increased after 12 week of anti-tuberculous therapy only in patients who had ‘Deficient’ 25-hydroxyvitamin D levels (&lt; 20 ng/mL) at initiation of treatment whilst this immune recovery was absent for TB patients with ‘Deficient’ 25- hydroxyvitamin D levels in the placebo group. This data suggests a role for 25-hydroxyvitamin D supplementation in boosting host immunity particularly in those with deficient 25 hydroxyvitamin D levels. It is possible that only patients with ‘Deficient’ 25 hydroxyvitamin D levels showed an improvement perhaps due to a critical level of 25-hydroxyvitamin D required by the host for optimal activation of IFN-g secretion and because this limit was already reached in the other 25-hydroxyvitamin D groups where no enhancement of mycobacterial antigen-induced IFN-g response was observed.</offsets></p><p><offsets xml_i="50672" xml_f="50964" txt_i="31547" txt_f="31839">Weight gain is routinely followed as an outpatient marker of clinical improvement in TB and we observed improvements in clinical status; i.e.; weight gain compared to the placebo group. This corresponds with the earliest reports of the benefits of vitamin D in TB patients published in 1848
[</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="50996" xml_f="50998" txt_i="31839" txt_f="31841">21</offsets></xref><offsets xml_i="51005" xml_f="51316" txt_i="31841" txt_f="32152">] that describes disease arrest, weight gain and reduction in mortality in patients with TB treated with cod liver oil compared to standard therapy alone. More recently, Martineau et al. demonstrated that a single oral dose of 2.5 mg (100,000 IU) of ergocalciferol significantly reduced growth of mycobacteria
[</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="51347" xml_f="51348" txt_i="32152" txt_f="32153">7</offsets></xref><offsets xml_i="51355" xml_f="51356" txt_i="32153" txt_f="32154">]</offsets><italic><offsets xml_i="51364" xml_f="51365" txt_i="32154" txt_f="32155">.</offsets></italic><offsets xml_i="51374" xml_f="51460" txt_i="32155" txt_f="32241"> A randomized, placebo controlled study on 67 Indonesian patients, by Nursyam et al.
[</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="51492" xml_f="51494" txt_i="32241" txt_f="32243">22</offsets></xref><offsets xml_i="51501" xml_f="51683" txt_i="32243" txt_f="32425">] reported that pulmonary TB patients given 420,000 IU of vitamin D over 6 weeks had significantly higher sputum conversion rates as compared to placebo (p 0.002). Martineau et al.
[</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="51714" xml_f="51715" txt_i="32425" txt_f="32426">8</offsets></xref><offsets xml_i="51722" xml_f="51770" txt_i="32426" txt_f="32474">] showed that 100,000 IUs of 25-hydroxyvitamin D</offsets><sub><offsets xml_i="51775" xml_f="51776" txt_i="32474" txt_f="32475">3</offsets></sub><offsets xml_i="51782" xml_f="51868" txt_i="32475" txt_f="32561"> supplementation significantly improved sputum conversion rates in patients with the T</offsets><italic><offsets xml_i="51876" xml_f="51879" txt_i="32561" txt_f="32564">aq1</offsets></italic><offsets xml_i="51888" xml_f="51938" txt_i="32564" txt_f="32614"> 25-hydroxyvitamin D receptor polymorphism of the </offsets><italic><offsets xml_i="51946" xml_f="51948" txt_i="32614" txt_f="32616">tt</offsets></italic><offsets xml_i="51957" xml_f="52083" txt_i="32616" txt_f="32742"> genotype. We speculate that this occurred due to broader effects of 25-hydroxyvitamin D on muscle, vascular and homeostasis
[</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="52115" xml_f="52117" txt_i="32742" txt_f="32744">23</offsets></xref><offsets xml_i="52124" xml_f="52125" txt_i="32744" txt_f="32745">-</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="52157" xml_f="52159" txt_i="32745" txt_f="32747">26</offsets></xref><offsets xml_i="52166" xml_f="52168" txt_i="32747" txt_f="32749">].</offsets></p><p><offsets xml_i="52175" xml_f="52516" txt_i="32750" txt_f="33091">We also found that the vitamin D treatment group had lesser disease (compared to placebo) by chest radiography after 12 weeks of therapy. This finding is consistent with a recent small placebo controlled trial on 24 children in Egypt that reported greater clinical and radiographic recovery after 1000 IUs of oral vitamin D supplementation
[</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="52548" xml_f="52550" txt_i="33091" txt_f="33093">27</offsets></xref><offsets xml_i="52557" xml_f="52719" txt_i="33093" txt_f="33255">] and a case report of an African –American patient with refractory, drug sensitive TB who improved only after being treated with 1,200,000 IU of ergoclaciferol
[</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="52751" xml_f="52753" txt_i="33255" txt_f="33257">28</offsets></xref><offsets xml_i="52760" xml_f="52762" txt_i="33257" txt_f="33259">].</offsets></p><p><offsets xml_i="52769" xml_f="52851" txt_i="33260" txt_f="33342">However, two recently published large randomised, controlled trials by Martineau
[</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="52882" xml_f="52883" txt_i="33342" txt_f="33343">8</offsets></xref><offsets xml_i="52890" xml_f="52910" txt_i="33343" txt_f="33363">] and Wejse et al.
[</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="52941" xml_f="52942" txt_i="33363" txt_f="33364">9</offsets></xref><offsets xml_i="52949" xml_f="53052" txt_i="33364" txt_f="33467">] found no difference in clinical outcomes or mortality after 10 mg (400,000 IU) of 25-hydroxyvitamin D</offsets><sub><offsets xml_i="53057" xml_f="53058" txt_i="33467" txt_f="33468">3</offsets></sub><offsets xml_i="53064" xml_f="53483" txt_i="33468" txt_f="33887"> and 300,000 IUs of cholecalciferol or placebo were given to 146 pulmonary TB patients in London, United Kingdom and 365 TB patients in Guinea-Bissau. It maybe speculated that the differences in response to 25-hydroxyvitamin D seen between our study and Wejse’s could be due to variations in VDR polymorphisms, variability in 25-hydroxyvitamin D dosages or differing levels of baseline serum 25-hydroxyvitamin D levels.</offsets></p><p><offsets xml_i="53490" xml_f="53847" txt_i="33888" txt_f="34245">We found 25-hydroxyvitamin D supplementation to be very safe, even in patients without deficiency. Only two patients in the vitamin D arm died during the study; one death was due to respiratory failure occurring within the initial 2 weeks of antituberculous therapy. It can be speculated whether this was a paradoxical response leading to acute lung injury.</offsets></p><p><offsets xml_i="53854" xml_f="53996" txt_i="34246" txt_f="34388">We used a ‘higher’ dose than the 2 recent negative studies reported by Wejse and Martineau et al., but closer to therapeutic recommendations
[</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="54028" xml_f="54030" txt_i="34388" txt_f="34390">29</offsets></xref><offsets xml_i="54037" xml_f="54038" txt_i="34390" txt_f="34391">-</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="54070" xml_f="54072" txt_i="34391" txt_f="34393">31</offsets></xref><offsets xml_i="54079" xml_f="54429" txt_i="34393" txt_f="34743">]. We speculate that this may account for the differences observed in the 2 groups at 12 weeks. We consider it a limitation of our study that we were unable to follow our patients to the end of treatment (6 months). It is possible that the benefits of 25-hydroxyvitamin D replacement may become more apparent between the groups with longer follow up.</offsets></p><p><offsets xml_i="54436" xml_f="54736" txt_i="34744" txt_f="35044">Another limitation of our study is that we did not collect information on dietary intakes However the study groups were well matched at enrolment and represented a variety of socioeconomic and ethnic groups, which may reduce the possibility that one study arm was disproportionately better nourished.</offsets></p></sec><sec sec-type="conclusions"><title><offsets xml_i="54781" xml_f="54791" txt_i="35046" txt_f="35056">Conclusion</offsets></title><p><offsets xml_i="54802" xml_f="55048" txt_i="35057" txt_f="35303">In summary, this study proposes that high dose vitamin D supplementation can lead to a more marked clinical and radiological recovery in all patients with pulmonary TB and boost host immune responses in patients deficient in 25-hydroxy vitamin D.</offsets></p></sec><sec><title><offsets xml_i="55070" xml_f="55082" txt_i="35305" txt_f="35317">Abbreviation</offsets></title><p><offsets xml_i="55093" xml_f="55454" txt_i="35318" txt_f="35679">IFN- g: Interferon gamma; MTB: Mycobacterium tuberculosis; MTBs: Mycobacterium tuberculosis sonicate; TB: Tuberculosis; DOTS: Directly Observed Therapy; BMI: Body Mass Index; MUAC: Mid Upper Arm Circumference; VDR 25-hydroxyvitamin: Vitamin D receptors; TLR: Toll-like receptor; MMP: Mycobacterium-induced matrix metalloproteases; ATT: Anti-tuberculous therapy.</offsets></p></sec><sec><title><offsets xml_i="55476" xml_f="55495" txt_i="35681" txt_f="35700">Competing interests</offsets></title><p><offsets xml_i="55506" xml_f="55559" txt_i="35701" txt_f="35754">The authors declare they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="55581" xml_f="55603" txt_i="35756" txt_f="35778">Authors’ contributions</offsets></title><p><offsets xml_i="55614" xml_f="56325" txt_i="35779" txt_f="36490">NS and MA had full access to the data and take responsibility for the integrity of the data analysis. MA contributed to data collection, analysis and interpretation of data. FA contributed to study design, data collection, analysis and interpretation of data. ZH contributed to study design, data collection, analysis and interpretation of data. NR contributed to data collection. FM contributed to study design, analysis and interpretation of data. NS contributed to study conception and design, supervision of research, analysis and interpretation of data, drafting and critical revision of the manuscript for intellectual content, and statistical analysis. All authors read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="56347" xml_f="56370" txt_i="36492" txt_f="36515">Pre-publication history</offsets></title><p><offsets xml_i="56381" xml_f="56445" txt_i="36516" txt_f="36580">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/13/22/prepub"><offsets xml_i="56547" xml_f="56598" txt_i="36581" txt_f="36632">http://www.biomedcentral.com/1471-2334/13/22/prepub</offsets></ext-link></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="56665" xml_f="56687" txt_i="36634" txt_f="36656">Supplementary Material</offsets></title><supplementary-material content-type="local-data" id="S1"><caption><title><offsets xml_i="56769" xml_f="56786" txt_i="36657" txt_f="36674">Additional file 1</offsets></title><p><bold><offsets xml_i="56803" xml_f="56813" txt_i="36675" txt_f="36685">Figure S1.</offsets></bold><offsets xml_i="56820" xml_f="56906" txt_i="36685" txt_f="36771"> Serum 25-hydroxy Vitamin D levels in the 2 study groups over the course of the study.</offsets></p></caption><media xlink:href="1471-2334-13-22-S1.tiff" mimetype="image" mime-subtype="tiff"><caption><p><offsets xml_i="57013" xml_f="57032" txt_i="36772" txt_f="36791">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title><offsets xml_i="57153" xml_f="57170" txt_i="36792" txt_f="36809">Additional file 2</offsets></title><p><bold><offsets xml_i="57187" xml_f="57197" txt_i="36810" txt_f="36820">Figure S2.</offsets></bold><offsets xml_i="57204" xml_f="57265" txt_i="36820" txt_f="36881"> Sputum Smear AFB Conversion rates in the 2 study groups002E.</offsets></p></caption><media xlink:href="1471-2334-13-22-S2.tiff" mimetype="image" mime-subtype="tiff"><caption><p><offsets xml_i="57372" xml_f="57391" txt_i="36882" txt_f="36901">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title><offsets xml_i="57512" xml_f="57529" txt_i="36902" txt_f="36919">Additional file 3</offsets></title><p><bold><offsets xml_i="57546" xml_f="57555" txt_i="36920" txt_f="36929">Table S1.</offsets></bold><offsets xml_i="57562" xml_f="57844" txt_i="36929" txt_f="37211"> ESAT6- and MTBs-stimulated IFN-g responses in whole blood cells of TB patients. Data depicts IFN-g ♦secretion in unstimulated and antigen stimulated whole blood cells. ESAT6 early secreted and T cell activated antigen-6 kDa; MTBs, Mycobacterium tuberculosis whole sonicate antigen.</offsets></p></caption><media xlink:href="1471-2334-13-22-S3.doc" mimetype="application" mime-subtype="msword"><caption><p><offsets xml_i="57958" xml_f="57977" txt_i="37212" txt_f="37231">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title><offsets xml_i="58098" xml_f="58115" txt_i="37232" txt_f="37249">Additional file 4</offsets></title><p><bold><offsets xml_i="58132" xml_f="58141" txt_i="37250" txt_f="37259">Table S2.</offsets></bold><offsets xml_i="58148" xml_f="58649" txt_i="37259" txt_f="37760"> ESAT6-induced IFN-g responses in patients with differing severity of TB. Patients with TB were divided into groups according to their TB scores; Severity Class I (TB score 0 to 5), Class II (TB score 6 – 7) and Class III (TB score ≥ 8). The data depicts IFN-g secretion in cellular supernatant of whole blood cells either unstimulated or after stimulation with ESAT6 (early secreted and T cell activated antigen-6 kDa). Values between groups were compared using determined by Kruskal-Wallis analysis.</offsets></p></caption><media xlink:href="1471-2334-13-22-S4.doc" mimetype="application" mime-subtype="msword"><caption><p><offsets xml_i="58763" xml_f="58782" txt_i="37761" txt_f="37780">Click here for file</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><caption><title><offsets xml_i="58903" xml_f="58920" txt_i="37781" txt_f="37798">Additional file 5</offsets></title><p><bold><offsets xml_i="58937" xml_f="58946" txt_i="37799" txt_f="37808">Table S3.</offsets></bold><offsets xml_i="58953" xml_f="59468" txt_i="37808" txt_f="38317"> ESAT6-stimulated IFN-g responses in whole blood cells of TB patients with differing 25-hydroxyvitamin D levels. Data depicts ESAT6-induced IFN-g secretion in whole blood cells after subtraction of spontaneous secretion from unstimulated cells (was equivalent to 0 pg/mL) in each case. Values between groups were compared using determined by Kruskal-Wallis analysis whereby values p &lt; 0.05 were considered significantly different. NS – not significant values. p &lt; 0.05 were considered significantly different.</offsets></p></caption><media xlink:href="1471-2334-13-22-S5.doc" mimetype="application" mime-subtype="msword"><caption><p><offsets xml_i="59582" xml_f="59601" txt_i="38318" txt_f="38337">Click here for file</offsets></p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>We thank the staff of the Ojha Institute for Chest Disease for their invaluable support for the study and Drs Fasih Rehman, Shafaq Mahmood, Babar Dildar, Farooq Oighor, Nadia Sharif, Arslan Rahatullah (Data Collection) and to Shafaq Mahmood, Mussarat Ashraf and the Department of Pathology and Microbiology, AKU (technical assistance).</p><sec><title>Financial/nonfinancial disclosures</title><p>The study was funded by a grant from the Aga Khan University Research Council. The authors report that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.</p></sec></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Stenger</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>DH</given-names></name><name><surname>Modlin</surname><given-names>RL</given-names></name><article-title>Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><issue>4</issue><fpage>2060</fpage><lpage>2063</lpage><pub-id pub-id-type="pmid">17675463</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Stenger</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wenzel</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>BH</given-names></name><name><surname>Krutzik</surname><given-names>SR</given-names></name><name><surname>Ochoa</surname><given-names>MT</given-names></name><name><surname>Schauber</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Meinken</surname><given-names>C</given-names></name><etal></etal><article-title>Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response</article-title><source>Science</source><year>2006</year><volume>311</volume><issue>5768</issue><fpage>1770</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1126/science.1123933</pub-id><pub-id pub-id-type="pmid">16497887</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Gibney</surname><given-names>KB</given-names></name><name><surname>MacGregor</surname><given-names>L</given-names></name><name><surname>Leder</surname><given-names>K</given-names></name><name><surname>Torresi</surname><given-names>J</given-names></name><name><surname>Marshall</surname><given-names>C</given-names></name><name><surname>Ebeling</surname><given-names>PR</given-names></name><name><surname>Biggs</surname><given-names>BA</given-names></name><article-title></article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><issue>3</issue><fpage>443</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1086/525268</pub-id><pub-id pub-id-type="pmid">18173355</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Sita-Lumsden</surname><given-names>A</given-names></name><name><surname>Lapthorn</surname><given-names>G</given-names></name><name><surname>Swaminathan</surname><given-names>R</given-names></name><name><surname>Milburn</surname><given-names>HJ</given-names></name><article-title>Reactivation of tuberculosis and vitamin D deficiency: the contribution of diet and exposure to sunlight</article-title><source>Thorax</source><year>2007</year><volume>62</volume><issue>11</issue><fpage>1003</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1136/thx.2006.070060</pub-id><pub-id pub-id-type="pmid">17526677</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Nnoaham</surname><given-names>KE</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><article-title>Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis</article-title><source>Int J Epidemiol</source><year>2008</year><volume>37</volume><issue>1</issue><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">18245055</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Talat</surname><given-names>N</given-names></name><name><surname>Perry</surname><given-names>S</given-names></name><name><surname>Parsonnet</surname><given-names>J</given-names></name><name><surname>Dawood</surname><given-names>G</given-names></name><name><surname>Hussain</surname><given-names>R</given-names></name><article-title>Vitamin d deficiency and tuberculosis progression</article-title><source>Emerg Infect Dis</source><year>2010</year><volume>16</volume><issue>5</issue><fpage>853</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.3201/eid1605.091693</pub-id><pub-id pub-id-type="pmid">20409383</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Martineau</surname><given-names>AR</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Newton</surname><given-names>SM</given-names></name><name><surname>Kampmann</surname><given-names>B</given-names></name><name><surname>Hall</surname><given-names>BM</given-names></name><name><surname>Packe</surname><given-names>GE</given-names></name><name><surname>Davidson</surname><given-names>RN</given-names></name><name><surname>Eldridge</surname><given-names>SM</given-names></name><name><surname>Maunsell</surname><given-names>ZJ</given-names></name><etal></etal><article-title>A single dose of vitamin D enhances immunity to mycobacteria</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><issue>2</issue><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1164/rccm.200701-007OC</pub-id><pub-id pub-id-type="pmid">17463418</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Martineau</surname><given-names>AR</given-names></name><name><surname>Timms</surname><given-names>PM</given-names></name><name><surname>Bothamley</surname><given-names>GH</given-names></name><name><surname>Hanifa</surname><given-names>Y</given-names></name><name><surname>Islam</surname><given-names>K</given-names></name><name><surname>Claxton</surname><given-names>AP</given-names></name><name><surname>Packe</surname><given-names>GE</given-names></name><name><surname>Moore-Gillon</surname><given-names>JC</given-names></name><name><surname>Darmalingam</surname><given-names>M</given-names></name><name><surname>Davidson</surname><given-names>RN</given-names></name><etal></etal><article-title>High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial</article-title><source>Lancet</source><year>2011</year><volume>377</volume><issue>9761</issue><fpage>242</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61889-2</pub-id><pub-id pub-id-type="pmid">21215445</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Wejse</surname><given-names>C</given-names></name><name><surname>Gomes</surname><given-names>VF</given-names></name><name><surname>Rabna</surname><given-names>P</given-names></name><name><surname>Gustafson</surname><given-names>P</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Lisse</surname><given-names>IM</given-names></name><name><surname>Andersen</surname><given-names>PL</given-names></name><name><surname>Glerup</surname><given-names>H</given-names></name><name><surname>Sodemann</surname><given-names>M</given-names></name><article-title>Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>179</volume><issue>9</issue><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1164/rccm.200804-567OC</pub-id><pub-id pub-id-type="pmid">19179490</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Wejse</surname><given-names>C</given-names></name><name><surname>Gustafson</surname><given-names>P</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Gomes</surname><given-names>VF</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Andersen</surname><given-names>PL</given-names></name><name><surname>Sodemann</surname><given-names>M</given-names></name><article-title>TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course</article-title><source>Scand J Infect Dis</source><year>2008</year><volume>40</volume><issue>2</issue><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1080/00365540701558698</pub-id><pub-id pub-id-type="pmid">17852907</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="book"><name><surname>Seaton</surname><given-names>A</given-names></name><name><surname>Seaton</surname><given-names>D</given-names></name><name><surname>Leitch</surname><given-names>AG</given-names></name><name><surname>Crofton</surname><given-names>J</given-names></name><source>Crofton and Douglas's respiratory diseases</source><year>1989</year><edition>4</edition><publisher-name>Oxford [England]: Blackwell Scientific</publisher-name></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="book"><name><surname>Seaton</surname><given-names>A</given-names></name><name><surname>Seaton</surname><given-names>D</given-names></name><name><surname>Leitch</surname><given-names>AG</given-names></name><name><surname>Crofton</surname><given-names>J</given-names></name><source>Crofton and Douglas’s respiratory diseases</source><year>2000</year><edition>5</edition><publisher-name>Malden, Mass: Blackwell Science</publisher-name></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="other"><name><surname>Hasan</surname><given-names>Z</given-names></name><name><surname>Rao</surname><given-names>N</given-names></name><name><surname>Salahuddin</surname><given-names>N</given-names></name><name><surname>Islam</surname><given-names>M</given-names></name><name><surname>Ashraf</surname><given-names>M</given-names></name><name><surname>Rottenberg</surname><given-names>ME</given-names></name><name><surname>Hussain</surname><given-names>R</given-names></name><article-title>M. tuberculosis sonicate induced IFNg, CXCL10 and IL10 can differentiate severity in tuberculosis</article-title><source>Scan J Immunol</source><volume>75</volume><fpage>220</fpage><lpage>226</lpage></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Coussens</surname><given-names>AK</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Hanifa</surname><given-names>Y</given-names></name><name><surname>Nikolayevskyy</surname><given-names>V</given-names></name><name><surname>Elkington</surname><given-names>PT</given-names></name><name><surname>Islam</surname><given-names>K</given-names></name><name><surname>Timms</surname><given-names>PM</given-names></name><name><surname>Venton</surname><given-names>TR</given-names></name><name><surname>Bothamley</surname><given-names>GH</given-names></name><name><surname>Packe</surname><given-names>GE</given-names></name><name><surname>Darmalingam</surname><given-names>M</given-names></name><name><surname>Davidson</surname><given-names>RN</given-names></name><name><surname>Milburn</surname><given-names>HJ</given-names></name><name><surname>Baker</surname><given-names>LV</given-names></name><name><surname>Barker</surname><given-names>RD</given-names></name><name><surname>Mein</surname><given-names>CA</given-names></name><name><surname>Bhaw-Rosun</surname><given-names>L</given-names></name><name><surname>Nuamah</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>DB</given-names></name><name><surname>Drobniewski</surname><given-names>FA</given-names></name><name><surname>Griffiths</surname><given-names>CJ</given-names></name><article-title>Martineau: Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment.AR</article-title><source>Proc Natl Acad Sci USA</source><year>2012</year><volume>109</volume><issue>38</issue><fpage>15449</fpage><lpage>15454</lpage><pub-id pub-id-type="doi">10.1073/pnas.1200072109</pub-id><pub-id pub-id-type="pmid">22949664</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Triebold</surname><given-names>KJ</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Bloom</surname><given-names>BR</given-names></name><article-title>An essential role for interferon g in resistance to Mycobacterium tuberculosis infection</article-title><source>J Exp Med</source><year>1993</year><volume>178</volume><issue>6</issue><fpage>2249</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1084/jem.178.6.2249</pub-id><pub-id pub-id-type="pmid">7504064</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Saunders</surname><given-names>BM</given-names></name><name><surname>Britton</surname><given-names>WJ</given-names></name><article-title>Life and death in the granuloma: immunopathology of tuberculosis</article-title><source>Immunol Cell Biol</source><year>2007</year><volume>85</volume><issue>2</issue><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/sj.icb.7100027</pub-id><pub-id pub-id-type="pmid">17213830</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Dlugovitzky</surname><given-names>D</given-names></name><name><surname>Bay</surname><given-names>ML</given-names></name><name><surname>Rateni</surname><given-names>L</given-names></name><name><surname>Urizar</surname><given-names>L</given-names></name><name><surname>Rondelli</surname><given-names>CF</given-names></name><name><surname>Largacha</surname><given-names>C</given-names></name><name><surname>Farroni</surname><given-names>MA</given-names></name><name><surname>Molteni</surname><given-names>O</given-names></name><name><surname>Bottasso</surname><given-names>OA</given-names></name><article-title>In vitro synthesis of interferon-g, interleukin-4, transforming growth factor-beta and interleukin-1 beta by peripheral blood mononuclear cells from tuberculosis patients: relationship with the severity of pulmonary involvement</article-title><source>Scand J Immunol</source><year>1999</year><volume>49</volume><issue>2</issue><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3083.1999.00492.x</pub-id><pub-id pub-id-type="pmid">10075027</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Ulrichs</surname><given-names>T</given-names></name><name><surname>Anding</surname><given-names>R</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name><name><surname>Munk</surname><given-names>ME</given-names></name><article-title>Numbers of IFN-gamma-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy</article-title><source>Int J Tuberc Lung Dis</source><year>2000</year><volume>4</volume><issue>12</issue><fpage>1181</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">11144463</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Harboe</surname><given-names>M</given-names></name><name><surname>Oettinger</surname><given-names>T</given-names></name><name><surname>Wiker</surname><given-names>HG</given-names></name><name><surname>Rosenkrands</surname><given-names>I</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name><article-title>Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG</article-title><source>Infect Immun</source><year>1996</year><volume>64</volume><issue>1</issue><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">8557334</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Black</surname><given-names>GF</given-names></name><name><surname>Weir</surname><given-names>RE</given-names></name><name><surname>Chaguluka</surname><given-names>SD</given-names></name><name><surname>Warndorff</surname><given-names>D</given-names></name><name><surname>Crampin</surname><given-names>AC</given-names></name><name><surname>Mwaungulu</surname><given-names>L</given-names></name><name><surname>Sichali</surname><given-names>L</given-names></name><name><surname>Floyd</surname><given-names>S</given-names></name><name><surname>Bliss</surname><given-names>L</given-names></name><name><surname>Jarman</surname><given-names>E</given-names></name><etal></etal><article-title>Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults</article-title><source>Clin Diagn Lab Immunol</source><year>2003</year><volume>10</volume><issue>4</issue><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">12853392</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>M</given-names></name><article-title>Cod liver oil and tuberculosis</article-title><source>BMJ</source><year>2011</year><volume>343</volume><fpage>d7505</fpage><pub-id pub-id-type="doi">10.1136/bmj.d7505</pub-id><pub-id pub-id-type="pmid">22187324</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Nursyam</surname><given-names>EW</given-names></name><name><surname>Amin</surname><given-names>Z</given-names></name><name><surname>Rumende</surname><given-names>CM</given-names></name><article-title>The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion</article-title><source>Acta Med Indones</source><year>2006</year><volume>38</volume><issue>1</issue><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16479024</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Moreira-Pfrimer</surname><given-names>LD</given-names></name><name><surname>Pedrosa</surname><given-names>MA</given-names></name><name><surname>Teixeira</surname><given-names>L</given-names></name><name><surname>Lazaretti-Castro</surname><given-names>M</given-names></name><article-title>Treatment of vitamin D deficiency increases lower limb muscle strength in institutionalized older people independently of regular physical activity: a randomized double-blind controlled trial</article-title><source>Ann Nutr Metab</source><year>2009</year><volume>54</volume><issue>4</issue><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1159/000235874</pub-id><pub-id pub-id-type="pmid">19729890</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Assimon</surname><given-names>MM</given-names></name><name><surname>Salenger</surname><given-names>PV</given-names></name><name><surname>El-Fawal</surname><given-names>HA</given-names></name><name><surname>Mason</surname><given-names>DL</given-names></name><article-title>Nutritional vitamin D supplementation in haemodialysis: A potential vascular benefit?</article-title><source>Nephrology (Carlton)</source><year>2012</year><volume>17</volume><issue>3</issue><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1797.2011.01555.x</pub-id><pub-id pub-id-type="pmid">22181351</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="other"><name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name><name><surname>Stocklin</surname><given-names>E</given-names></name><name><surname>Sidelnikov</surname><given-names>E</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Orav</surname><given-names>EJ</given-names></name><name><surname>Stahelin</surname><given-names>HB</given-names></name><name><surname>Wolfram</surname><given-names>S</given-names></name><name><surname>Jetter</surname><given-names>A</given-names></name><name><surname>Schwager</surname><given-names>J</given-names></name><etal></etal><article-title>Oral supplementation with 25(OH)D(3) versus vitamin D(3) : effects on 25(OH)D levels, lower extremity function, blood pressure and markers of innate immunity</article-title><source>J Bone Miner Res</source><year>2011</year><comment>Epub ahead of print</comment><pub-id pub-id-type="doi">10.1002/jbmr.551</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="other"><name><surname>Eftekhari</surname><given-names>MH</given-names></name><name><surname>Akbarzadeh</surname><given-names>M</given-names></name><name><surname>Dabbaghmanesh</surname><given-names>MH</given-names></name><name><surname>Hasanzadeh</surname><given-names>J</given-names></name><article-title>Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients</article-title><source>Asia Pac J Clin Nutr</source><volume>20</volume><issue>4</issue><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">22094836</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Morcos</surname><given-names>MM</given-names></name><name><surname>Gabr</surname><given-names>AA</given-names></name><name><surname>Samuel</surname><given-names>S</given-names></name><name><surname>Kamel</surname><given-names>M</given-names></name><name><surname>el Baz</surname><given-names>M</given-names></name><name><surname>el Beshry</surname><given-names>M</given-names></name><name><surname>Michail</surname><given-names>RR</given-names></name><article-title>Vitamin D administration to tuberculous children and its value</article-title><source>Boll Chim Farm</source><year>1998</year><volume>137</volume><issue>5</issue><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">9689902</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Yamshchikov</surname><given-names>A</given-names></name><name><surname>Oladele</surname><given-names>A</given-names></name><name><surname>Leonard</surname><given-names>M</given-names></name><name><surname>Blumberg</surname><given-names>H</given-names></name><name><surname>Ziegler</surname><given-names>T</given-names></name><name><surname>Tangpricha</surname><given-names>V</given-names></name><article-title>Vitamin D as adjunctive therapy in refractory pulmonary tuberculosis: a case report</article-title><source>South Med J</source><year>2009</year><volume>102</volume><issue>6</issue><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1097/SMJ.0b013e3181a5d37e</pub-id><pub-id pub-id-type="pmid">19434014</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Biancuzzo</surname><given-names>RM</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Klein</surname><given-names>EK</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Bibuld</surname><given-names>D</given-names></name><name><surname>Reitz</surname><given-names>R</given-names></name><name><surname>Salameh</surname><given-names>W</given-names></name><name><surname>Ameri</surname><given-names>A</given-names></name><name><surname>Tannenbaum</surname><given-names>AD</given-names></name><article-title>Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D</article-title><source>J Clin Endocrinol Metab</source><year>2008</year><volume>93</volume><issue>3</issue><fpage>677</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">18089691</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Malabanan</surname><given-names>A</given-names></name><name><surname>Veronikis</surname><given-names>IE</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><article-title>Redefining vitamin D insufficiency</article-title><source>Lancet</source><year>1998</year><volume>351</volume><issue>9105</issue><fpage>805</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">9519960</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Przybelski</surname><given-names>R</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Krueger</surname><given-names>D</given-names></name><name><surname>Engelke</surname><given-names>JA</given-names></name><name><surname>Walbrun</surname><given-names>F</given-names></name><name><surname>Binkley</surname><given-names>N</given-names></name><article-title>Rapid correction of low vitamin D status in nursing home residents</article-title><source>Osteoporos Int</source><year>2008</year><volume>19</volume><issue>11</issue><fpage>1621</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1007/s00198-008-0619-x</pub-id><pub-id pub-id-type="pmid">18421544</pub-id></mixed-citation></ref></ref-list></back></article>